– Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition –

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions.

Current Chief Financial Officer Keith A. Goldan has decided to retire from the position and will remain with the Company through the end of 2026 to support the transition. Mr. Goldan led Syndax’s financial and capital strategy during an important period in the Company’s history. He played a key role in the successful launches of Revuforj and Niktimvo and in initiatives that strengthened the Company’s pipeline and innovative R&D platform.

“On behalf of the Board and our entire team, I thank Keith for his many valuable contributions and wish him all the best in his well-earned retirement,” said Michael A. Metzger, Chief Executive Officer of Syndax. “Keith was integral to Syndax’s transition into a commercial-stage company and the delivery of three FDA approvals, and he helped lay the foundation for our long-term success.”

Mr. Metzger continued, “We are delighted to welcome Aaron to Syndax. He brings decades of experience guiding biopharma companies through commercial expansion and major milestones. The Board and I are confident he will successfully lead our financial strategy and organization as we scale our commercial business, advance our deep pipeline and deliver long-term shareholder value.”

“I am thrilled to join Syndax at such a pivotal moment in the Company’s evolution,” said Aaron A. Ondrey. “Syndax has built an impressive commercial platform with two approved medicines and a compelling pipeline targeting significant market opportunities. I look forward to partnering with Michael and the broader Syndax team to build on the Company’s leadership position and its strong financial foundation.”

“It has been a privilege to serve as CFO at Syndax and partner with Michael and a highly talented and dedicated team,” said Keith A. Goldan, Chief Financial Officer of Syndax. “I am proud of everything we have accomplished together and the positive impact this work continues to have for patients. I am confident Syndax is well positioned for continued success long into the future.”

Mr. Ondrey brings extensive leadership and financial experience across both pre-commercial and commercial-stage biopharmaceutical companies. Most recently, he served as Chief Financial Officer of Beren Therapeutics, where he oversaw finance, investor relations, and manufacturing operations. Prior to joining Beren Therapeutics, Mr. Ondrey served as Chief Financial Officer of Rocket Pharmaceuticals, where he led the company’s financial strategy as it prepared for its transition to a commercial-stage organization. Before Rocket Pharmaceuticals, he was Chief Financial Officer and Senior Vice President at Mirati Therapeutics, where he supported the commercialization of KRAZATI® and played a key role in the company’s acquisition by Bristol Myers Squibb in January 2024. Earlier in his career, Mr. Ondrey held senior leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals, building extensive experience in corporate finance, strategic planning, commercialization, and operational execution.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax’s product candidates, the acceptance of Syndax and its partners’ products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj’s or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax’s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

All financial figures are in Canadian dollars unless otherwise noted

CALGARY, Alberta, Nov. 02, 2026 (GLOBE NEWSWIRE) — Gibson Energy Inc. (TSX:GEI) (“Gibson” or the “Company”) announced today its financial and operating results for the three and nine months ended September 30, 2026.

  Key Highlights:

  • Delivered record adjusted EBITDA(1) of $193 million and record adjusted EBITDA per share, reflecting strong performance across both Infrastructure and Marketing
  • Generated record Infrastructure adjusted EBITDA(1) of $177 million and record Infrastructure adjusted EBITDA per share, driven primarily by a full quarter of contributions from the Chauvin Infrastructure Assets
  • Achieved Marketing adjusted EBITDA(1) of $35 million, supported by continued strength in refined product margins, the benefits of a more diversified product mix, and improved crude marketing opportunities
  • Sanctioned the Chauvin pipeline expansion, which will increase system capacity by approximately 50%, supported by strong commercial interest and growing production in the Mannville, with an expected in-service date during the first half of 2028
  • Continued our industry-leading safety performance, surpassing 500 days without a recordable injury while safely bringing the Wink-to-Gateway Integration Project into service and completing the integration of the Chauvin assets into our operations
 
     

“Gibson delivered an exceptional third quarter, with record results across the business,” said Curtis Philippon, President & Chief Executive Officer. “Chauvin continues to exceed our expectations, and we are pleased to sanction an expansion that will increase pipeline capacity by approximately 50%. It is a great example of the kind of disciplined infrastructure investment we want to make: supported by our customers, closely connected to our existing assets and capable of delivering attractive returns. In the U.S., we also placed our Wink-to-Gateway Integration Project into service, enhancing connectivity across our network and positioning Gateway to capture additional volumes. With improving Canadian market access and growing producer activity, the opportunity set in front of Gibson is as strong as we have seen in some time. We are well positioned to turn those opportunities into meaningful growth and long-term value for shareholders.”

Financial Highlights:

  • Infrastructure adjusted EBITDA(1) of $177 million in the third quarter, a $23 million increase from the third quarter of 2025, primarily driven by strong performance from the Chauvin Infrastructure Assets, higher overall throughput, including record volumes moved to TMX through Edmonton, ongoing optimization of our existing assets, and benefits from the Company’s 2026 restructuring initiatives
  • Marketing adjusted EBITDA(1) of $35 million in the third quarter, a $28 million increase from the third quarter of 2025, primarily driven by strong refining margins resulting from elevated crack spreads, highlighting the benefits of the Company’s product diversification strategy
  • Adjusted EBITDA(1) on a consolidated basis of $193 million in the third quarter, a $46 million increase from the third quarter of 2025, primarily reflecting stronger Infrastructure and Marketing results and adjustments for unrealized gains and losses on financial instruments in both periods, partially offset by higher General and Administrative costs
  • Net income of $77 million in the third quarter, a $31 million increase from the third quarter of 2025, primarily due to the factors affecting segment adjusted EBITDA as noted above, partially offset by higher income tax expense and finance costs
  • Distributable Cash Flow(1) of $120 million in the third quarter, a $34 million increase from the third quarter of 2025, primarily due to the factors contributing to higher adjusted EBITDA as noted above, partially offset by higher finance cost and current income tax expense
  • Dividend payout ratio(2) of 82% and net debt to adjusted EBITDA(2) ratio of 3.9x on a trailing twelve-month basis, with both metrics expected to improve as a full 12 months of contributions from the Chauvin acquisition are reflected

Strategic Developments and Highlights:

  • In November, the Board declared a quarterly dividend of $0.45 per common share, payable on January 15, 2027, to shareholders of record at the close of business on December 30, 2026
  • In October, placed the Wink-to-Gateway Integration Project into service, enhancing connectivity and operational flexibility at Gateway
  • In September, the Company’s NCIB was renewed for an additional one-year period, enabling the Company to repurchase and cancel up to 7,251,988 common shares, representing 5% of the Company’s public float
  • In July, the Company closed its offering of $400 million 4.45% senior unsecured medium-term notes due January 9, 2034

(1) Adjusted EBITDA and distributable cash flow are non-GAAP financial measures. See the “Specified Financial Measures” section of this release.
(2) Net debt to adjusted EBITDA ratio and dividend payout ratio are non-GAAP financial ratios. See the “Specified Financial Measures” section of this release.

Management’s Discussion and Analysis and Financial Statements 
The 2026 third quarter Management’s Discussion and Analysis and unaudited Condensed Consolidated Financial Statements provide a detailed explanation of Gibson’s financial and operating results for the three months and nine months ended September 30, 2026, as compared to the three months and nine months ended September 30, 2025. These documents are available at www.gibsonenergy.com and on SEDAR+ at www.sedarplus.ca.

Earnings Conference Call & Webcast Details
A conference call and webcast will be held to discuss the 2026 third quarter financial and operating results at 8:00am ABT (9:00am ET) on Tuesday, November 3, 2026.

To register for the call, view dial-in numbers, and obtain a dial-in PIN, please access the following URL:

https://register-conf.media-server.com/register/BI8015be24fb1e49ffb93a019531a832fd?utm

Registration at least five minutes prior to the conference call is recommended.

This call will also be broadcast live on the Internet and may be accessed directly at the following URL:

https://edge.media-server.com/mmc/p/h5qy8qeq

The webcast will remain accessible for a 12-month period at the above URL.

Supplementary Information
Gibson has also made available certain supplementary information regarding the 2026 third quarter financial and operating results, available at www.gibsonenergy.com.

About Gibson
Gibson is a leading liquids infrastructure company providing storage, optimization, processing, gathering, and waterborne vessel loading services for liquids and refined products. Headquartered in Calgary, Alberta, the Company’s operations are located across North America, with core terminal assets in Hardisty and Edmonton, Alberta, Ingleside and Wink, Texas, and a facility in Moose Jaw, Saskatchewan.

Gibson shares trade under the symbol GEI and are listed on the Toronto Stock Exchange. For more information, visit www.gibsonenergy.com.

Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information and statements (collectively, “forward-looking statements”). All statements other than statements of historical fact are forward-looking statements. The use of any of the words “expect”, “will” and similar expressions are intended to identify forward-looking statements. Forward-looking statements included or referred to in this press release include, but are not limited to, statements concerning: the development, construction and completion of the Chauvin pipeline expansion project, including its expected increase in system capacity and anticipated in-service date; Gibson’s long-term growth strategy and ability to create long-term shareholder value, including through infrastructure investments capable of delivering attractive returns; Gateway’s positioning to capture additional volumes following the completion of the Wink-to-Gateway Integration Project; improving Canadian market access and growing producer activity, and Gibson’s ability to realize on opportunities relating thereto to produce meaningful growth and create long term value for shareholders; expectations regarding the Company’s dividend payout ratio and net debt to adjusted EBITDA metrics, including their expected improvement and the expected timing and payment of the quarterly dividend. These statements are based on assumptions that the Chauvin pipeline expansion will proceed on the anticipated schedule and within expected costs, with necessary approvals and customer support; that Canadian market access and producer activity will continue to support growth opportunities; that the Chauvin Infrastructure Assets will contribute to Gibson’s financial results as expected; and that customer demand and market conditions will support Gateway’s ability to capture additional volumes as expected. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this press release should not be unduly relied upon. These statements speak only as of the date of this press release. The Company does not undertake any obligations to publicly update or revise any forward-looking statements except as required by securities law. Actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous risks and uncertainties including, but not limited to, construction delays or cost overruns on the Chauvin pipeline expansion, changes in producer activity, customer demand or market access, and lower-than-expected contributions from the Chauvin Infrastructure Assets, as well as the risks and uncertainties described in “Forward-Looking Information” and “Risk Factors” included in the Company’s Annual Information Form dated February 17, 2026, and Management’s Discussion and Analysis dated November 2, 2026, as filed on SEDAR+ and available on the Gibson website at www.gibsonenergy.com.

For further information, please contact:

Investor Relations
Phone: (403) 776-3077
Email: investor.relations@gibsonenergy.com

Media
Phone: (403) 476-6334
Email: communications@gibsonenergy.com

Specified Financial Measures
This press release refers to certain financial measures that are not determined in accordance with GAAP, including non-GAAP financial measures and non-GAAP financial ratios. Readers are cautioned that non-GAAP financial measures and non-GAAP financial ratios do not have standardized meanings prescribed by GAAP and, therefore, may not be comparable to similar measures presented by other entities. Management considers these to be important supplemental measures of the Company’s performance and believes these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in industries with similar capital structures.

For further details on these specified financial measures, including relevant reconciliations, see the “Specified Financial Measures” section of the Company’s MD&A for the three and nine months ended September 30, 2026 and 2025, which is incorporated by reference herein and is available on Gibson’s SEDAR+ profile at www.sedarplus.ca and Gibson’s website at www.gibsonenergy.com.

        a)    Adjusted EBITDA

Noted below is the reconciliation to the most directly comparable GAAP measures of the Company’s segmented and consolidated adjusted EBITDA for the three and nine months ended September 30, 2026, and 2025:

Three months ended September 30, Infrastructure Marketing Corporate and Adjustments Total
($ thousands) 2026 2025 2026   2025 2026   2025   2026   2025  
                 
Segment profit 174,134 149,101 43,589   4,403 —   —   217,723   153,504  
Unrealized loss (gain) on derivative financial instruments 1,372 3,503 (9,063 ) 2,339 —   —   (7,691 ) 5,842  
General and administrative — — —   — (17,997 ) (13,298 ) (17,997 ) (13,298 )
Adjustments to share of profit from equity accounted investee 1,568 1,549 —   — —   —   1,568   1,549  
Renewable virtual power purchase agreement — — —   — (715 ) (520 ) (715 ) (520 )
Adjusted EBITDA 177,074 154,153 34,526   6,742 (18,712 ) (13,818 ) 192,888   147,077  

Nine months ended September 30, Infrastructure Marketing Corporate and Adjustments Total
($ thousands) 2026 2025   2026   2025   2026   2025   2026   2025  
                 
Segment profit 491,016 459,820   60,235   27,331   —   —   551,251   487,151  
Unrealized loss (gain) on derivative financial instruments 6,751 (2,177 ) (7,825 ) (12,816 ) —   —   (1,074 ) (14,993 )
General and administrative — —   —   —   (52,668 ) (40,638 ) (52,668 ) (40,638 )
Adjustments to share of profit from equity accounted investee 4,690 3,896   —   —   —   —   4,690   3,896  
Executive transition costs — —   —   —   —   2,405   —   2,405  
Renewable virtual power purchase agreement — —   —   —   (1,732 ) (2,142 ) (1,732 ) (2,142 )
Adjusted EBITDA 502,457 461,539   52,410   14,515   (54,400 ) (40,375 ) 500,467   435,679  

  Three months ended September 30,
 
($ thousands) 2026   2025  
     
Net Income 77,026   45,694  
     
Income tax expense 27,302   12,439  
Depreciation, amortization, and impairment charges 48,905   43,398  
Finance costs, net 39,621   35,094  
Unrealized (gain) loss on derivative financial instruments (8,190 ) 5,842  
Unrealized loss (gain) on renewable virtual power purchase agreement 73   (1,436 )
Share-based compensation 5,210   4,104  
Acquisition and integration costs 970   —  
Adjustments to share of profit from equity accounted investee 1,568   1,549  
Corporate foreign exchange loss and other 403   393  
Adjusted EBITDA 192,888   147,077  

  Nine months ended September 30,
 
($ thousands) 2026   2025  
     
Net Income 158,558   156,346  
     
Income tax expense 52,245   46,580  
Depreciation, amortization, and impairment charges 145,860   128,923  
Finance costs, net 113,567   103,329  
Unrealized gain on derivative financial instruments (1,573 ) (14,993 )
Unrealized gain on renewable virtual power purchase agreement (22 ) (9,180 )
Share-based compensation 14,306   11,826  
Restructuring costs 8,125   —  
Acquisition and integration costs 6,162   —  
Adjustments to share of profit from equity accounted investee 4,690   3,896  
Corporate foreign exchange (gain) loss and other (1,451 ) 6,547  
Executive transition costs —   2,405  
Adjusted EBITDA 500,467   435,679  

        b)    Distributable Cash Flow

The following is a reconciliation of distributable cash flow from operations to its most directly comparable GAAP measure, cash flow from operating activities:

  Three months ended September 30,
  Nine months ended September 30,  
($ thousands) 2026   2025   2026   2025  
         
Cash flow from operating activities 212,583   195,572   429,766   416,804  
Adjustments:        
Changes in non-cash working capital and taxes paid (24,418 ) (50,826 ) 42,825   7,526  
Replacement capital (14,629 ) (12,863 ) (37,448 ) (33,326 )
Cash interest expense, including capitalized interest (37,486 ) (33,413 ) (107,074 ) (97,341 )
Acquisition and integration costs 970   —   6,162   —  
Restructuring costs (1) —   —   6,125   —  
Executive transition costs (1) —   —   —   2,405  
Lease payments (6,780 ) (5,353 ) (19,889 ) (18,448 )
Current income tax (10,579 ) (7,567 ) (30,821 ) (20,016 )
Distributable cash flow 119,661   85,550   289,646   257,604  

  Twelve months ended September 30,
 
($ thousands) 2026   2025  
     
Cash flow from operating activities 523,121   484,080  
Adjustments:    
Changes in non-cash working capital and taxes paid 88,231   61,504  
Replacement capital (51,962 ) (45,053 )
Cash interest expense, including capitalized interest (141,405 ) (129,272 )
Acquisition and integration costs (1) 6,162   —  
Restructuring costs (1) 6,125   —  
Executive transition costs (1) —   8,709  
Lease payments (27,059 ) (24,511 )
Current income tax (34,071 ) (26,701 )
Distributable cash flow 369,142   328,756  
         

(1)        Costs adjusted on an incurred basis.

        c)    Dividend Payout Ratio

  Twelve months ended September 30,
 
($ thousands) 2026   2025  
Distributable cash flow 369,142   328,756  
Dividends declared 303,342   278,095  
Dividend payout ratio 82 % 85 %

        d)    Net Debt To Adjusted EBITDA Ratio

  Twelve months ended September 30,
 
($ thousands) 2026   2025  
     
Current and long-term debt 2,932,035   2,677,669  
Lease liabilities 106,468   51,395  
Less: unsecured hybrid notes (450,000 ) (450,000 )
Less: cash and cash equivalents (92,816 ) (58,460 )
     
Net debt 2,495,687   2,220,604  
Adjusted EBITDA 645,475   565,361  
Net debt to adjusted EBITDA ratio 3.9   3.9  
     
Infrastructure segment EBITDA 662,955   608,468  
Less:    
General and administrative (68,038 ) (52,685 )
Executive transition costs —   8,709  
Renewable virtual power purchase agreement (2,462 ) (2,855 )
  592,455   561,636  
Infrastructure leverage 4.2   4.0  

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on November 2, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com 

Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com 

– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase –

– Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and KMT2Ar acute leukemia; 20% q/q growth in new patients – 

– Niktimvo™ (axatilimab-csfr) net revenue of $67.4 million in 3Q26, a 47% y/y increase, resulting in Syndax collaboration revenue of $22.6 million –

– New revumenib data expected in 4Q26 from clinical trials and real-world studies spanning the acute leukemia treatment continuum and multiple genetic subtypes –

– Company to host a conference call today at 4:30 p.m. ET –

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided a business update.

“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting. We continue to have the dominant share of new patients across all age groups starting a menin inhibitor and the vast majority of revenue for the class, underscoring our position as the market leader. Importantly, a growing number of both R/R KMT2Ar and NPM1m patients are proceeding to a stem cell transplant after receiving Revuforj and then resuming therapy afterward, a dynamic that positions the business for long-term growth as the average duration of therapy extends,” said Michael A. Metzger, Chief Executive Officer.

Mr. Metzger continued, “We look forward to sharing new Revuforj combination data in the fourth quarter that reinforce our confidence that our ongoing pivotal frontline trials could transform the treatment paradigm for newly diagnosed AML. We remain well positioned to be the first to deliver a menin inhibitor in the frontline, unlocking a multi-billion-dollar opportunity. With growing revenue from two medicines, a robust pipeline generating multiple blockbuster opportunities, world-class R&D capabilities, and a strong balance sheet, Syndax is poised to deliver long-term value.”

Recent Business Highlights and Anticipated Milestones

Revuforj® (revumenib)

  • Achieved $60.7 million in Revuforj net revenue in the third quarter of 2026, a 90% increase over the third quarter of 2025 and an 11% increase over the second quarter of 2026. New patients and total prescriptions increased by approximately 20% and 13%, respectively, in the third quarter of 2026 compared to the second quarter of 2026. The double-digit growth in net revenue, new patients, and total prescriptions reflects robust uptake in both Revuforj indications and a growing number of relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) and NPM1-mutated (NPM1m) patients proceeding to hematopoietic stem cell transplant (HSCT) and then resuming therapy in the post-transplant setting.
    • Claims data indicate that approximately 50% of R/R KMT2Ar patients proceed to HSCT after receiving Revuforj, of which about 60% have resumed therapy post-transplant. Notably, the data also indicate that approximately 40% of R/R NPM1m patients proceed to HSCT after receiving Revuforj, of which about 50% have resumed therapy post-transplant.
  • In October 2026, Revuforj received the Best Product for Rare/Orphan Diseases award from The Galien Foundation, one of the world’s most prestigious awards for biomedical research and innovation. Additionally, Revuforj was named as one of TIME’s Best Inventions of 2026 in the Medical and Healthcare category.
  • The Company expects to have a major presence at upcoming medical meetings, with the presentation in the fourth quarter of 2026 of new/updated revumenib data including:
    • Frontline data from the BEAT AML trial of revumenib in combination with venetoclax/azacitidine in NPM1m and KMT2Ar acute myeloid leukemia (AML)
    • Frontline data from the SAVE trial of the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax in NPM1m, KMT2Ar, or NUP98-rearranged (NUP98r) AML
    • Frontline data from a Phase 1 trial of revumenib in combination with intensive chemotherapy in NPM1m, KMT2Ar, or NUP98r AML
    • Post-transplant maintenance data
    • Real-world evidence from multiple centers
    • Data from INTERCEPT, a Phase 1 trial evaluating revumenib as pre-emptive therapy for measurable residual disease (MRD) or early relapse among patients with NPM1m or KMT2Ar AML
  • The Company expects to publish safety and efficacy data from R/R NUP98r acute leukemia patients treated with revumenib in the fourth quarter of 2026.
  • Published preclinical revumenib data showing that menin is a novel dependency in proliferative megakaryocytes, major drivers of myelofibrosis (MF), in Cancer Cell in July 2026. These data provide the basis for the Company’s plans to develop SNDX-62122, an internally developed, next-generation menin inhibitor, for MF.
  • Multiple clinical trials evaluating revumenib across the acute leukemia treatment continuum are ongoing, such as:
    • EVOLVE-2: A pivotal, Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed NPM1m (primary efficacy analysis population) and KMT2Ar AML patients who are unfit for intensive chemotherapy. The trial is being conducted in collaboration with the HOVON network, a leading cooperative clinical trial group with extensive experience studying novel therapies for hematologic malignancies.
    • REVEAL-ND: A pivotal, Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1m AML patients.
    • SAVE: A Phase 1/2 trial evaluating an all-oral combination of revumenib with venetoclax and decitabine/cedazuridine in pediatric and adult patients with newly diagnosed and R/R AML or mixed-lineage acute leukemia harboring either NPM1m, KMT2Ar, or NUP98r alterations. The trial is being conducted by investigators from MD Anderson Cancer Center.
    • Intensive chemotherapy: Two ongoing Phase 1 trials evaluating the combination of revumenib with intensive chemotherapy (7+3) in newly diagnosed NPM1m or KMT2Ar acute leukemia patients.
    • BEAT AML: A Phase 1b trial evaluating the combination of revumenib with venetoclax and azacitidine in newly diagnosed older adults (≥60 years) with NPM1m or KMT2Ar AML. The trial is being conducted as part of the Leukemia & Lymphoma Society’s Beat AML® Master Clinical Trial.
    • Post-transplant maintenance: A Phase 1 trial evaluating the safety and preliminary efficacy of revumenib as post-transplant maintenance in patients with KMT2Ar or NPM1m acute leukemia. The trial is being conducted by investigators from the City of Hope Medical Center.
    • Break Through Cancer: A Phase 2 trial studying whether the combination of revumenib and venetoclax can eliminate MRD in patients with AML and extend progression-free survival. The trial is being conducted by Break Through Cancer, a collaboration between leading U.S. cancer research centers.
    • INTERCEPT: A Phase 1 trial evaluating the use of novel therapies, including revumenib, to target MRD and early relapse in AML. The trial is being conducted by the Australasian Leukaemia and Lymphoma Group as part of the INTERCEPT AML master clinical trial.
  • The Company expects the RAVEN trial to initiate in the fourth quarter of 2026. RAVEN is a Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients who would be considered eligible, or fit, for intensive chemotherapy.
  • The Company expects the MenTain Phase 2 trial to initiate in the first quarter of 2027. MenTain will be the first randomized, placebo-controlled trial specifically focused on evaluating revumenib as post-transplant maintenance.

Niktimvo™ (axatilimab-csfr)

  • Achieved $67.4 million in Niktimvo net revenue in the third quarter of 2026, a 47% increase over the third quarter of 2025 and a 12% increase over the second quarter of 2026. Syndax and Incyte are co-commercializing Niktimvo. Syndax records 50% of the Niktimvo net commercial profit, defined as net product revenue minus the cost of sales and commercial expenses. Syndax’s share of the Niktimvo product contribution, reported as collaboration revenue, was $22.6 million in the third quarter of 2026.
  • In October 2026, data supporting the safety and feasibility of reduced-frequency dosing of axatilimab in patients with recurrent or refractory chronic graft-versus-host disease (GVHD) were published in Blood Advances. Data from the pivotal AGAVE-201 trial show that transition from axatilimab 0.3 mg/kg every two weeks to 0.6 mg/kg every four weeks was feasible and well tolerated. Patients had a prolonged duration of therapy after the switch (median of 21 months), and 84% remained on treatment as of the data cutoff, suggesting ongoing clinical benefit.
  • Two trials evaluating axatilimab in patients with newly diagnosed chronic GVHD are ongoing, including a Phase 2 trial in combination with ruxolitinib and a Phase 3 trial in combination with corticosteroids.
    • The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027.
    • The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028.
  • In October 2026, the Company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint. The safety and tolerability profile observed in MAXPIRe was consistent with previous clinical studies of axatilimab, with no new safety signals identified. Based on the results observed, Syndax does not plan to move forward with further development of axatilimab in IPF. The results from the MAXPIRe trial do not affect ongoing trials of axatilimab in other potential indications.

Pipeline Assets

SNDX-4321

  • In July 2026, the Company announced the expansion of its pipeline with SNDX-4321, a mutant-selective, CNS-penetrant, allosteric EGFR inhibitor. SNDX-4321 is in development for non-small cell lung cancer (NSCLC) patient populations with significant unmet needs, such as those with L858R mutations, CNS metastases, atypical activating mutations, or acquired resistance to current therapies. In contrast to ATP-site directed third- and fourth-generation EGFR inhibitors, SNDX-4321 is a novel allosteric inhibitor which binds at a pocket adjacent to the ATP site that is only accessible in the presence of L858R and certain other EGFR mutations.
  • The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027.

SNDX-62122

  • In July 2026, the Company announced the selection of SNDX-62122, a next-generation menin inhibitor, for development in MF. SNDX-62122 is the first candidate from a library of internally developed, wholly owned next-generation menin inhibitors that the Company intends to advance into new areas.
  • The Company expects to submit an IND and initiate a Phase 1 trial of SNDX-62122 in MF in the fourth quarter of 2027. The development of SNDX-62122 will be informed by a Phase 1/2 proof-of-principle trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027.

Corporate Updates

  • On November 2, 2026, the Company announced Keith Goldan’s decision to retire from his role as Chief Financial Officer and the appointment of Aaron A. Ondrey as Chief Financial Officer, effective November 9, 2026. Mr. Ondrey brings to Syndax more than 25 years of financial and operational leadership experience across the biotechnology industry, with deep expertise in financial management, corporate strategy, commercialization, and mergers and acquisitions. 

Third Quarter 2026 Financial Results

As of September 30, 2026, Syndax had cash, cash equivalents, and short- and long-term investments of $551.1 million and 90.0 million common shares outstanding.

Total revenue for the third quarter of 2026 was $83.3 million, which consisted of $60.7 million in Revuforj net revenue and $22.6 million in Niktimvo collaboration revenue. The Niktimvo collaboration revenue is derived from the $67.4 million in Niktimvo net revenue that was previously reported by the Company’s partner Incyte for the third quarter 2026. Syndax records 50% of the Niktimvo net commercial profit, defined as net revenue (recorded by Incyte) minus the cost of sales and commercial expenses.

Third quarter 2026 research and development expenses increased to $67.5 million from $56.3 million for the comparable prior year period. The year-over-year change was primarily the result of increased expenses associated with frontline trials evaluating revumenib in combination with standard-of-care agents in the treatment of AML.

Third quarter 2026 selling, general and administrative expenses decreased to $43.7 million from $44.9 million for the comparable prior year period. The year-over-year change was primarily the result of lower commercial expenses due to launch costs incurred in 2025 for Revuforj and Niktimvo that were not incurred in the same period in 2026.

For the three months ended September 30, 2026, Syndax reported a net loss attributable to common stockholders of $49.4 million, or $0.55 per share, compared to a net loss attributable to common stockholders of $60.7 million, or $0.70 per share, for the comparable prior year period.

Financial Guidance

For the full year of 2026, the Company continues to expect total research and development plus selling, general and administrative expenses to be approximately $400 million, excluding the impact of $50 million in estimated non-cash stock compensation expense.

Syndax expects that its cash, cash equivalents and short- and long-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the Company to reach profitability.

Conference Call and Webcast

In connection with the earnings release, Syndax’s management team will host a conference call and live audio webcast at 4:30 p.m. ET today, November 2, 2026.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company’s website. Alternatively, the conference call may be accessed through the following:

Conference ID: Syndax3Q26
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://sndx-3q26.open-exchange.net/

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.

About Revuforj® (revumenib)

Revuforj (revumenib) is the first and only menin inhibitor that is FDA approved for the treatment of adult and pediatric patients one year and older with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options or R/R acute leukemia with a KMT2A translocation as determined by an FDA-authorized test.

Multiple trials of revumenib are ongoing or planned across the treatment landscape, including in combination with standard of care therapies in newly diagnosed patients with NPM1m or KMT2Ar AML.

About Niktimvo™ (axatilimab-csfr)

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).

In 2016, Syndax licensed exclusive worldwide rights to develop and commercialize axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialization license agreement for axatilimab in chronic GVHD and any future indications.

Axatilimab is being studied in frontline combination trials in chronic GVHD, including a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774).

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “could,” “estimate,” “expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax’s product candidates, the acceptance of Syndax and its partners’ products in the marketplace, sales, marketing, manufacturing and distribution requirements, the potential use of its product candidates to treat various cancer indications and fibrotic diseases, Syndax’s expected full year total operating expenses, including its estimated non-cash stock compensation expense, and Syndax’s expectation that its cash, cash equivalents and short-term investments, combined with its anticipated product revenue, collaboration revenue and interest income, will enable the Company to reach profitability. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj’s or Niktimvo’s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax’s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Niktimvo is a trademark of Incyte.
All other trademarks are the property of their respective owners.

Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

   
SYNDAX PHARMACEUTICALS, INC.  
(unaudited)  
CONDENSED CONSOLIDATED BALANCE SHEETS  
               
      September 30,     December 31,  
(In thousands) 2026     2025  
Cash, cash equivalents, short and long-term investments $ 551,079     $ 394,070  
Total assets $ 692,671     $ 529,706  
Total liabilities $ 709,851     $ 465,076  
Total stockholders’ (deficit) equity $ (17,180 )   $ 64,630  
               
Common stock outstanding   89,989,347       87,405,979  
Common stock and common stock equivalents*   116,512,240       103,437,561  
               
*Common stock and common stock equivalents:          
  Common stock   89,989,347       87,405,979  
  Common stock warrants (pre-funded)   –       285,714  
    Common stock and pre-funded stock warrants   89,989,347       87,691,693  
  Options to purchase common stock   13,302,121       13,128,306  
  Restricted Stock Units   3,123,422       2,617,562  
  Conversion of convertible notes   10,097,350       –  
    Total common stock and common stock equivalents   116,512,240       103,437,561  

   
SYNDAX PHARMACEUTICALS, INC.  
(unaudited)  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
                           
      Three Months Ended September 30,     Nine Months Ended September 30,  
(In thousands, except share and per share data) 2026     2025     2026     2025  
Revenue          
  Product revenue, net $ 60,743       32,007     $ 164,366       80,649  
  Collaboration revenue, net   22,555       13,864       56,584       22,975  
Total revenues   83,298       45,871       220,950       103,624  
Operating expenses:                      
  Cost of product sales $ 13,996       2,100     $ 19,837       4,264  
  Research and development   67,481       56,280       194,362       180,143  
  Selling, general and administrative   43,716       44,917       122,843       129,753  
Total operating expenses   125,193       103,297       337,042       314,160  
Loss from operations   (41,895 )     (57,426 )     (116,092 )     (210,536 )
Other (expense) income, net:                      
  Royalty interest expense   (11,812 )     (8,283 )     (35,777 )     (24,186 )
  Convertible note interest expense   (1,164 )     –       (1,719 )     –  
  Other interest expense   (2 )     –       (4 )     (6 )
  Interest income   5,593       5,269       12,900       18,402  
  Other expense   (153 )     (275 )     (777 )     (1,082 )
Total other (expense) income, net   (7,538 )     (3,289 )     (25,377 )     (6,872 )
Net loss $ (49,433 )   $ (60,715 )   $ (141,469 )   $ (217,408 )
Other comprehensive loss:                      
  Unrealized (loss) gain on marketable securities   (1,528 )     240       (2,120 )     362  
Other comprehensive loss   (50,961 )     (60,475 )     (143,589 )     (217,046 )
Net loss per share:                      
Basic and diluted loss per share attributable to common stockholders $ (0.55 )   $ (0.70 )   $ (1.59 )   $ (2.51 )
                           
Weighted-average common shares used in calculating:                      
Basic and diluted loss per share attributable to common stockholders   89,789,842       86,620,992       89,017,885       86,531,218  

MIDLAND, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Viper Energy, Inc. (NASDAQ:VNOM) (“Viper,” “we,” “our” or the “Company”), a subsidiary of Diamondback Energy, Inc. (NASDAQ:FANG) (“Diamondback”), today announced financial and operating results for the third quarter ended September 30, 2026.

THIRD QUARTER FINANCIAL HIGHLIGHTS

  • Net income of $300 million; Net income margin of 45%
  • Adjusted EBITDA1 of $596 million; Adjusted EBITDA margin1 of 90%
  • Cash flows from operating activities of $447 million; Operating cash flow margin of 68%
  • Free Cash Flow1 of $520 million; Free Cash Flow margin1 of 79%
  • Declared Q3 2026 base cash dividend of $0.50 per Class A common share
  • Repurchased approximately 2.1 million Class A shares for approximately $90 million
  • Total debt of $2.4 billion as of September 30, 2026; Net debt1 of $2.4 billion as of September 30, 2026

THIRD QUARTER OPERATIONAL HIGHLIGHTS

  • Average daily production of 69,076 bo/d (141,152 boe/d)
  • As previously announced, on July 1, 2026, completed the Riverbend Acquisition
  • On September 1, 2026, closed the previously announced 2026 Drop Down of approximately 1,000 net royalty acres in the Permian Basin from Diamondback and related subsidiaries in exchange for approximately 3.8 million OpCo units and an equivalent number of shares of Class B common stock (the “2026 Drop Down”)
  • Lease bonus income of $4 million from 21 executed leases
  • 689 total gross (19.0 net) horizontal wells turned to production
  • As of September 30, 2026, Viper’s acreage had the following ongoing development activity:
    • 104 active horizontal rigs, representing approximately 40% of the Permian Basin total
    • 1,965 gross (38.9 net) horizontal wells2 either being drilled or completed
    • 1,404 gross (36.4 net) horizontal wells2 with line-of-sight to near-term development

__________________
1 NON-GAAP DISCLOSURES – For a definition of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Free Cash Flow margin, Net Debt and reconciliations of such non-GAAP financial metrics to their respective most directly comparable GAAP metrics, please see “Non-GAAP Financial Measures” below.
2 Average lateral length of wells normalized to 10,000 feet.


MCELROY RANCH ACQUISITION

During the month of September, in two separate but related transactions, Viper acquired mineral and royalty interests from third-party sellers for an aggregate purchase price of approximately $529 million, subject to customary post-closing adjustments and including certain transaction costs and $49 million of deferred consideration payable in equal quarterly installments through June 2029 (collectively, the “McElroy Ranch Acquisition”). Acquisition highlights are as follows:

  • Approximately 7,359 net royalty acres located in Upton and Crane Counties
  • Concentrated ownership of an approximately 12% net royalty interest across roughly 60,000 gross acres in an expected core geologic fairway of Barnett development in the western Midland Basin
  • Asset is 96% undeveloped with an expected 40.9 net inventory locations
    • Only 21 currently producing gross (1.7 net) horizontal locations across the entire Ranch
    • Chevron operates approximately 27% of the total net inventory, including approximately 50% of net undeveloped Barnett inventory
    • Diamondback operates approximately 15% of the total net inventory
    • Concentrated nature of mineral ownership will enable potential trades to accelerate development in the coming years
  • Offsetting Barnett wells that have at least 12 months of production data indicate an average estimated ultimate recovery of approximately 80 bo/ft
  • Stable production of approximately 400 bo/d from existing vertical wells
  • Forecasted peak production on the Ranch in the range of 5,000 bo/d over the next decade

PENDING BUCKHORN ACQUISITION
On September 14, 2026, Viper entered into a definitive purchase and sale agreement to acquire certain mineral and royalty interests from a group of entities collectively called Buckhorn Minerals (the “Pending Buckhorn Acquisition”) in exchange for $280 million cash and approximately 1.8 million shares of Viper’s Class A common stock, subject to customary closing adjustments. The cash portion of the transaction is expected to be funded through a combination of cash on hand and borrowings under the Company’s revolving credit facility. The transaction is expected to close in the fourth quarter of 2026, subject to the satisfaction of customary closing conditions. Acquisition highlights are as follows:

  • 1,552 net royalty acres, substantially all of which are in the Midland Basin; approximately 80% overlap with existing Viper acreage position
  • Midland Basin primary operators include ExxonMobil (47%) and Diamondback (29%)
  • Asset is 61% undeveloped with an expected 17.4 net inventory locations
    • Approximately 20% of Midland Basin acreage in units with zero producing horizontal wells; expected to support efficient full stack development in coming years
    • 47% of net inventory in Viper’s estimation of remaining top quartile inventory in the Midland Basin, and 70% of net inventory within the top half of remaining inventory (as determined by expected internal rate of return for the respective operators)
  • Expected next 12 months’ average daily oil production of approximately 1,500 bo/d
  • Expect pro forma net debt at year end 2026 of approximately $2.4 billion, equating to pro forma leverage of approximately 1.0x last twelve months Adjusted EBITDA3

__________________
3 NON-GAAP DISCLOSURES – For a definition of Adjusted EBITDA and Net Debt and reconciliations of such non-GAAP financial metrics to their respective most directly comparable GAAP metrics, please see “Non-GAAP Financial Measures” below.

OTHER RECENT EVENTS AND FORWARD OUTLOOK

  • Inclusive of the Pending Buckhorn Acquisition, initiating average daily production guidance for Q4 2026 of 70,000 to 71,000 bo/d (141,500 to 143,500 boe/d)
  • Increasing average daily production guidance for full year 2026 to 67,250 to 67,750 bo/d (137,000 to 138,000 boe/d)
  • Repurchased approximately 0.4 million Class A shares in Q4 2026 (to date) for approximately $17 million

“Viper’s momentum carried through the third quarter, with average daily oil production growing more than six percent quarter over quarter on the strength of recent acquisitions and continued development activity from both Diamondback and our third-party operators. Reflecting this continued momentum, we are again increasing our full year 2026 production guidance to 67,500 barrels of oil per day at the midpoint. The quarter also marked the first under our new return of capital framework, through which we declared our increased base dividend of $0.50 per Class A share while continuing to opportunistically repurchase shares,” said Kaes Van’t Hof, Chief Executive Officer of Viper.

Mr. Van’t Hof continued, “The McElroy Ranch Acquisition and Pending Buckhorn Acquisition announced today represent the continued execution of our differentiated consolidation strategy. The acquisitions combine to extend the quality and duration of our inventory, adding nearly 60 net locations across two largely undeveloped assets. The McElroy Ranch asset brings concentrated mineral ownership in an expected core fairway of emerging Barnett development, while the Pending Buckhorn Acquisition adds high-quality Midland Basin inventory with approximately 80% overlap with our existing footprint. Notably, we funded, or expect to fund, these acquisitions primarily with cash, delivering on the commitment we made when we revised our return of capital framework to pursue accretive M&A with minimal reliance on equity. These acquisitions add years of visible development to Viper’s portfolio and reinforce the durability of our long-term per-share growth outlook.”

FINANCIAL UPDATE

Viper’s third quarter 2026 average unhedged realized prices were $87.65 per barrel of oil, $0.96 per Mcf of natural gas and $24.02 per barrel of natural gas liquids, resulting in a total equivalent realized price of $50.52/boe.

Viper’s third quarter 2026 average hedged realized prices were $86.55 per barrel of oil, $0.66 per Mcf of natural gas and $24.02 per barrel of natural gas liquids, resulting in a total equivalent realized price of $49.51/boe.

During the third quarter of 2026, the Company recorded total operating income of $661 million and consolidated net income (including non-controlling interest) of $300 million.

As of September 30, 2026, the Company had a cash balance of $10 million and total debt outstanding (excluding debt issuance costs, discounts and premiums) of $2.4 billion, resulting in net debt (as defined and reconciled below) of $2.4 billion. Viper’s outstanding long-term debt as of September 30, 2026 consisted of $500 million in aggregate principal amount of its 4.900% Senior Notes due 2030, $1.1 billion in aggregate principal amount of its 5.700% Senior Notes due 2035 and $810 million of borrowings on its revolving credit facility, leaving approximately $1.2 billion available for future borrowings and approximately $1.2 billion of total liquidity.

THIRD QUARTER 2026 CASH DIVIDEND & CAPITAL RETURN PROGRAM

Viper announced today that the Company’s Board of Directors (the “Board”) declared a base cash dividend of $0.50 per Class A common share for the third quarter of 2026, payable on November 19, 2026 to Class A common stockholders of record at the close of business on November 12, 2026.

During the third quarter of 2026, Viper repurchased approximately 2.1 million shares of the Company’s Class A common stock for an aggregate purchase price of approximately $90 million, excluding excise tax (average price of $43.01 per share).

In total, since the initiation of Viper’s common stock repurchase program on November 9, 2020 through October 30, 2026, the Company has repurchased approximately 26.1 million shares of common stock (including both Class A shares and Class B shares paired with OpCo Units) for an aggregate purchase price of approximately $844 million, excluding excise tax (average price of $32.30 per share) and has approximately $906 million remaining on its share buyback authorization. Future cash dividends and stock repurchases are at the discretion of the Board and are subject to a number of factors discussed in Viper’s reports filed with the U.S. Securities and Exchange Commission (“SEC”).

OPERATIONS UPDATE

During the third quarter of 2026, Viper estimates that 689 gross (19.0 net 100% royalty interest) horizontal wells, normalized to lateral length of 10,000 feet, with an average royalty interest of 2.8% were turned to production on its acreage position. Of these 689 gross wells, Diamondback is the operator of 123 gross wells, with an average royalty interest of 9.4%, and the remaining 566 gross wells, with an average royalty interest of 1.3%, are operated by third parties.

As of September 30, 2026, Viper’s footprint of mineral and royalty interests was approximately 98,098 net royalty acres.

Our gross well information for the third quarter ended September 30, 2026:

  Diamondback
Operated
  Third-Party
Operated
  Total
Q3 2026 horizontal wells turned to production(1):          
Gross wells  123   566   689
Net 100% royalty interest wells  11.6   7.4   19.0
Average percent net royalty interest  9.4%   1.3%   2.8%
           
Horizontal producing well count(1):          
Gross wells  4,613   21,834   26,447
Net 100% royalty interest wells  290.9   334.1   625.0
Average percent net royalty interest  6.3%   1.5%   2.4%
           
Horizontal active development well count(1):          
Gross wells  303   1,662   1,965
Net 100% royalty interest wells  17.5   21.4   38.9
Average percent net royalty interest  5.8%   1.3%   2.0%
           
Line of sight wells(1):          
Gross wells  370   1,034   1,404
Net 100% royalty interest wells  22.5   13.9   36.4
Average percent net royalty interest  6.1%   1.3%   2.6%

(1) Average lateral length normalized to 10,000 feet.

The 1,965 gross wells currently in the process of active development are those wells that have been spud and are expected to be turned to production within approximately the next six to eight months. Further in regard to the active development on Viper’s asset base, there are currently 104 gross rigs operating on Viper’s acreage, 11 of which are operated by Diamondback. The 1,404 line-of-sight wells are those that are not currently in the process of active development, but for which Viper has reason to believe that they will be turned to production within approximately the next 15 to 18 months. The expected timing of these line-of-sight wells is based primarily on permitting by third-party operators or Diamondback’s current expected completion schedule. Existing permits or active development of Viper’s royalty acreage does not ensure that those wells will be turned to production.

GUIDANCE UPDATE

Below is Viper’s guidance for the full year 2026, as well as average production guidance for Q4 2026. This guidance gives effect to the 2026 Drop Down and the McElroy Ranch Acquisition that closed during September 2026 as well as the Pending Buckhorn Acquisition that is expected to close in the fourth quarter of 2026.

   
  Viper Energy, Inc.
   
Q4 2026 Net Production – Mbo/d 70.00 – 71.00
Q4 2026 Net Production – Mboe/d 141.50 – 143.50
Full Year 2026 Net Production – Mbo/d 67.25 – 67.75
Full Year 2026 Net Production – Mboe/d 137.00 – 138.00
   
Unit costs ($/boe)  
Depreciation, Depletion and Amortization $14.75 – $17.25
Cash G&A $0.70 – $0.90
Non-Cash Share-Based Compensation $0.10 – $0.20
Net Interest Expense $1.90 – $2.40
   
Production and Ad Valorem Taxes (% of Revenue) ~7%
Cash Tax Rate (% of Pre-Tax Income Attributable to the Company)(1) 27% – 30%

(1) Pre-tax income attributable to the Company is a non-GAAP measure. We are not able to forecast the most directly comparable GAAP measure – Income (loss) before income taxes – due to the high variability and difficulty in predicting certain items that affect Income (loss) before income taxes, such as future commodity prices, pace of development and production of our mineral interests, and factors impacting the Company’s ownership of the net assets of VNOM Holding Company LLC such as repurchases of our Class A common shares, Class B common shares or VNOM Holding Company LLC’s units (OpCo Units), or conversions of our Class B common shares and/or OpCo Units to Class A common shares.

CONFERENCE CALL

Viper will host a conference call and webcast for investors and analysts to discuss its results for the third quarter of 2026 on Tuesday, November 3, 2026 at 10:00 a.m. CT. Access to the live audio-only webcast, and replay which will be available following the call, may be found here. The live webcast of the earnings conference call will also be available via Viper’s website at www.viperenergy.com under the “Investor Relations” section of the site.

About Viper Energy, Inc.

Viper is a corporation formed by Diamondback to own, acquire and exploit oil and natural gas properties in North America, with a focus on owning and acquiring mineral and royalty interests in oil-weighted basins, primarily the Permian Basin in West Texas. For more information, please visit www.viperenergy.com.

Investors and others should note that Viper announces material financial and operational information to our investors using our investor relations website (https://www.viperenergy.com/investors/overview), press releases, SEC filings and public conference calls and webcasts. The information we post through our investor relations website may be deemed material. Accordingly, investors should monitor our investor relations website in addition to following our press releases, SEC filings and public conference calls and webcasts.

About Diamondback Energy, Inc.

Diamondback is an independent oil and natural gas company headquartered in Midland, Texas focused on the acquisition, development, exploration and exploitation of unconventional, onshore oil and natural gas reserves primarily in the Permian Basin in West Texas. For more information, please visit www.diamondbackenergy.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks, uncertainties, and assumptions that could cause the results to differ materially from such statements. All statements, other than statements of historical fact, including statements regarding Viper’s: future performance; business strategy; future operations; estimates and projections of operating income, losses, costs and expenses, returns, cash flow, and financial position; production levels on properties in which Viper has mineral and royalty interests; developmental activity by other operators; reserve estimates and Viper’s ability to replace or increase reserves; the anticipated benefits from the Sitio Acquisition or other strategic transactions (including the Riverbend Acquisition, 2026 Drop Down, McElroy Ranch Acquisition, Pending Buckhorn Acquisition or any other acquisitions or divestitures); and plans and objectives (including Diamondback’s plans for developing Viper’s acreage and Viper’s cash dividend policy and common stock repurchase program) are forward-looking statements. When used in this news release, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) as they relate to Viper are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Viper believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond its control. Accordingly, forward-looking statements are not guarantees of Viper’s future performance and the actual outcomes could differ materially from what Viper expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: changes in supply and demand levels for oil, natural gas and natural gas liquids and the resulting impact on the price for those commodities; the impact of public health crises, including epidemic or pandemic diseases and any related company or government policies or actions; actions taken by the members of OPEC and its non-OPEC allies (OPEC+) affecting the production and pricing of oil, as well as other domestic and global political, economic, or diplomatic developments; changes in general economic, business or industry conditions, including changes in foreign currency exchange rates, interest rates, inflation rates, or instability in the financial sector; regional supply and demand factors, including delays, curtailment delays or interruptions of production on our mineral and royalty acreage, or governmental orders, rules or regulations that impose production limits on such acreage; federal and state legislative and regulatory initiatives relating to hydraulic fracturing, including the effect of existing and future laws and governmental regulations; physical and transition risks relating to climate change and changing political and social perspectives on climate change and other environmental, social and governance factors; risks from our cash dividend policy and uncertainties over our future dividends; restrictions on the use of water, including limits on the use of produced water by our operators and a moratorium on new produced water well permits imposed by the Texas Railroad Commission in an effort to control induced seismicity in the Permian Basin; significant declines in prices for oil, natural gas, or natural gas liquids, which could require recognition of significant impairment charges; changes in U.S. energy, environmental, monetary and trade policies, including with respect to tariffs or other trade barriers and any resulting trade tensions; conditions in the capital, financial and credit markets, including the availability and pricing of capital for drilling and development by our limited number of operators and our ability to replace operators in time of bankruptcy or default; changes in availability or cost of rigs, equipment, raw materials, supplies and oilfield services impacting our operators; the inherent uncertainties over our estimated reserves, the development of our proved undeveloped reserves or the yield from project areas on our properties; the geographical concentration of our producing properties and reserves in the Permian Basin and in a small number of producing horizons; changes in safety, health, environmental, tax and other regulations or requirements impacting us or our operators (including those addressing air emissions, water management, or the impact of global climate change); security threats, including cybersecurity threats and disruptions to our business from breaches of Diamondback’s information technology systems, or from breaches of information technology systems of our operators or third parties with whom we transact business; lack of, or disruption in, access to adequate and reliable electrical power, internet and telecommunication infrastructure, information and computer systems, transportation, processing, storage and other facilities impacting our operators; severe weather conditions and natural disasters; geopolitics, regional conflicts, acts of war or terrorist acts and the governmental or military response thereto; changes in the financial strength of counterparties to the revolving credit facility and hedging contracts of our operating subsidiary; our substantial indebtedness and changes in our credit rating; failure to develop or acquire additional reserves and identify, complete or integrate acquisitions such as the Riverbend Acquisition, McElroy Ranch Acquisition or Pending Buckhorn Acquisition; our operational dependence on, and control by, Diamondback and potential conflicts of interest thereof; and other risks and factors discussed in Viper’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent periodic filings with the SEC, including its Forms 10-K, 10-Q and 8-K, and other filings Viper makes with the SEC, which can be obtained free of charge on the SEC’s web site at http://www.sec.gov.

In light of these factors, the events anticipated by Viper’s forward-looking statements may not occur at the time anticipated or at all. Moreover, new risks emerge from time to time. Viper cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements made in this news release. All forward-looking statements speak only as of the date of this news release or, if earlier, as of the date they were made. Viper does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

 
Viper Energy, Inc.
Condensed Consolidated Statements of Operations
(unaudited, in millions, except per share amounts, shares in thousands)
               
  Three Months Ended
September 30,
  Nine Months Ended
September 30,
    2026       2025       2026       2025  
Operating income:              
Oil income  $ 557     $ 332     $ 1,567     $ 774  
Natural gas income    19       15       36       40  
Natural gas liquids income    80       46       207       110  
Royalty income    656       393       1,810       924  
Lease bonus income    4       8       29       19  
Lease bonus income—related party    —       17       5       17  
Other operating income    1       —       5       —  
Total operating income    661       418       1,849       960  
Costs and expenses:              
Production and ad valorem taxes    44       27       122       65  
Depreciation, depletion, and amortization    206       182       607       373  
Impairment    —       360       —       360  
General and administrative expenses    5       6       18       12  
General and administrative expenses—related party    7       4       18       11  
Other operating expenses    —       15       4       25  
Total costs and expenses    262       594       769       846  
Income (loss) from operations    399       (176 )     1,080       114  
Other income (expense):              
Interest expense, net    (30 )     (32 )     (81 )     (60 )
Gain (loss) on derivative instruments, net    (31 )     18       (13 )     21  
Other income (expense), net    1       (33 )     (1 )     (33 )
Total other income (expense), net    (60 )     (47 )     (95 )     (72 )
Income (loss) before income taxes    339       (223 )     985       42  
Provision for (benefit from) income taxes    39       (26 )     139       2  
Net income (loss)    300       (197 )     846       40  
Net income (loss) attributable to non-controlling interest    160       (120 )     467       5  
Net income (loss) attributable to Viper Energy, Inc.  $ 140     $ (77 )   $ 379     $ 35  
               
Net income (loss) attributable to common shares:              
Basic  $ 0.72     $ (0.52 )   $ 1.99     $ 0.25  
Diluted  $ 0.72     $ (0.52 )   $ 1.99     $ 0.25  
Weighted average number of common shares outstanding:              
Basic    193,988       148,882       189,721       133,741  
Diluted    193,988       148,882       189,721       133,868  

 
Viper Energy, Inc.
Condensed Consolidated Balance Sheets
(unaudited, in millions, except par values and share data)
       
  September 30,   December 31,
    2026       2025  
Assets      
Current assets:      
Cash and cash equivalents  $ 10     $ 13  
Royalty income receivable (net of allowance for credit losses)    496       262  
Royalty income receivable—related party    19       88  
Prepaid expenses and other current assets    43       50  
Total current assets    568       413  
Property:      
Oil and natural gas properties:      
Proved properties    10,102       9,746  
Unproved properties    5,213       4,910  
Other property, equipment and land    8       8  
Accumulated depletion, depreciation, amortization and impairment    (3,062 )     (2,455 )
Total property and equipment, net    12,261       12,209  
Deferred income taxes (net of allowances)    132       33  
Other assets    41       16  
Total assets  $ 13,002     $ 12,671  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accrued liabilities  $ 73     $ 107  
Other current liabilities    23       4  
Total current liabilities    96       111  
Long-term debt, net    2,394       2,186  
Other long-term liabilities    36       11  
Total liabilities    2,526       2,308  
Stockholders’ equity:      
Class A Common Stock, $0.000001 par value: 1,000,000,000 shares authorized; 193,043,950 shares issued and outstanding at September 30, 2026, and 170,942,687 shares issued and outstanding at December 31, 2025    —       —  
Class B Common Stock, $0.000001 par value: 1,000,000,000 shares authorized; 168,551,337 shares issued and outstanding at September 30, 2026, and 187,023,698 shares issued and outstanding at December 31, 2025    —       —  
Additional paid-in capital    5,386       4,726  
Retained earnings (accumulated deficit)    (263 )     (278 )
Total Viper Energy, Inc. stockholders’ equity    5,123       4,448  
Non-controlling interest    5,353       5,915  
Total equity    10,476       10,363  
Total liabilities and stockholders’ equity  $ 13,002     $ 12,671  

 
Viper Energy, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited, in millions)
               
  Three Months Ended September 30,   Nine Months Ended September 30,
    2026       2025       2026       2025  
Cash flows from operating activities:              
Net income (loss)  $ 300     $ (197 )   $ 846     $ 40  
Adjustments to reconcile net income (loss) to net cash provided by operating activities:              
Provision for (benefit from) deferred income taxes    (10 )     (36 )     (15 )     (42 )
Depreciation, depletion, and amortization    206       182       607       373  
Impairment    —       360       —       360  
(Gain) loss on derivative instruments, net    31       (18 )     13       (21 )
Net cash receipts (payments) on derivatives    (13 )     11       23       23  
Other    6       38       12       42  
Changes in operating assets and liabilities:              
Royalty income receivable    (24 )     14       (223 )     (40 )
Royalty income receivable—related party    8       (25 )     69       (33 )
Accrued liabilities    (5 )     (33 )     (46 )     (40 )
Other    (52 )     (15 )     (24 )     (8 )
Net cash provided by (used in) operating activities    447       281       1,262       654  
Cash flows from investing activities:              
Acquisitions of oil and natural gas properties    (843 )     (1,205 )     (964 )     (1,484 )
Acquisitions of oil and natural gas properties—related party    —       108       (12 )     (873 )
Proceeds from sale of oil and natural gas properties    1       —       612       —  
Net cash provided by (used in) investing activities    (842 )     (1,097 )     (364 )     (2,357 )
Cash flows from financing activities:              
Proceeds from debt    960       2,350       1,480       3,090  
Repayments of debt    (245 )     (842 )     (1,275 )     (1,568 )
Net proceeds from public offering    —       —       —       1,232  
Repurchases of shares of Class A Common Stock as part of the repurchase program    (90 )     (90 )     (272 )     (100 )
Repurchases of OpCo Units as part of the repurchase program    —       —       (46 )     —  
Dividends to stockholders    (130 )     (68 )     (363 )     (228 )
Dividends to Diamondback   (138 )     (90 )     (353 )     (258 )
Dividends to other non-controlling interest    (28 )     (8 )     (73 )     (25 )
Other    (1 )     (21 )     1       (24 )
Net cash provided by (used in) financing activities    328       1,231       (901 )     2,119  
Net increase (decrease) in cash, cash equivalents and restricted cash    (67 )     415       (3 )     416  
Cash, cash equivalents and restricted cash at beginning of period    77       28       13       27  
Cash, cash equivalents and restricted cash at end of period  $ 10     $ 443     $ 10     $ 443  

 
Viper Energy, Inc.
Selected Operating Data
(unaudited)
           
  Three Months Ended
  September 30, 2026   June 30, 2026   September 30, 2025
Production Data:          
Oil (MBbls)    6,355     5,922     5,160
Natural gas (MMcf)    19,799     18,949     14,655
Natural gas liquids (MBbls)    3,331     3,147     2,412
Combined volumes (Mboe)(1)    12,986     12,227     10,015
           
Average daily oil volumes (bo/d)    69,076     65,077     56,087
Average daily combined volumes (boe/d)    141,152     134,363     108,859
           
Average prices:          
Oil ($/Bbl)  $ 87.65   $ 98.28   $ 64.34
Natural gas ($/Mcf)  $ 0.96   $ 0.05   $ 1.02
Natural gas liquids ($/Bbl)  $ 24.02   $ 23.83   $ 19.07
Combined price ($/boe)(2)  $ 50.52   $ 53.82   $ 39.24
           
Oil, hedged ($/Bbl)(3)  $ 86.55   $ 96.42   $ 63.76
Natural gas, hedged ($/Mcf)(3)  $ 0.66   $ 1.48   $ 1.77
Natural gas liquids ($/Bbl)(3)  $ 24.02   $ 23.83   $ 19.07
Combined price, hedged ($/boe)(3)  $ 49.51   $ 55.12   $ 40.04
           
Average Costs ($/boe):          
Production and ad valorem taxes  $ 3.39   $ 3.52   $ 2.70
General and administrative – cash component    0.69     0.65     0.80
Total operating expense – cash  $ 4.08   $ 4.17   $ 3.50
           
General and administrative – non-cash stock compensation expense  $ 0.23   $ 0.25   $ 0.20
Interest expense, net  $ 2.31   $ 1.96   $ 3.20
Depreciation, depletion, and amortization  $ 15.86   $ 15.95   $ 18.17

(1) Bbl equivalents are calculated using a conversion rate of six Mcf per one Bbl.
(2) Realized price net of all deducts for gathering, transportation and processing.
(3) Hedged prices reflect the impact of cash settlements of our matured commodity derivative transactions on our average sales prices.

NON-GAAP FINANCIAL MEASURES

ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN

Adjusted EBITDA and Adjusted EBITDA margin are supplemental non-GAAP (as defined below) financial measures that are used by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. The Company defines Adjusted EBITDA as net income (loss) attributable to the Company, plus net income (loss) attributable to non-controlling interest (“net income (loss)”) before interest expense, net, non-cash share-based compensation expense, depreciation, depletion and amortization, impairment, non-cash (gain) loss on derivative instruments, provision for (benefit from) income taxes and other non-cash or non-recurring operating expenses. The Company defines Adjusted EBITDA margin as Adjusted EBITDA divided by total operating income. Adjusted EBITDA and Adjusted EBITDA margin are not measures of net income as determined by United States’ generally accepted accounting principles (“GAAP”). Management believes Adjusted EBITDA and Adjusted EBITDA margin are useful because they allow them to evaluate the Company’s operating performance and compare the results of its operations from period to period without regard to its financing methods or capital structure. Adjusted EBITDA should not be considered as an alternative to, or more meaningful than, net income, royalty income, cash flow from operating activities or any other measure of financial performance or liquidity presented as determined in accordance with GAAP. Adjusted EBITDA margin should not be considered as an alternative to, or more meaningful than, net income margin, gross margin, or any other measure of financial performance or liquidity presented as determined in accordance with GAAP. Certain items excluded from Adjusted EBITDA and Adjusted EBITDA margin are significant components in understanding and assessing a company’s financial performance, such as a company’s cost of capital and tax structure, as well as the historic costs of depreciable assets, none of which are components of Adjusted EBITDA or Adjusted EBITDA margin.

The following table presents a reconciliation of the GAAP financial measure of net income (loss) to the non-GAAP financial measure of Adjusted EBITDA and a reconciliation of the GAAP ratio of net income margin to the non-GAAP ratio of Adjusted EBITDA margin:

 
Viper Energy, Inc.
Adjusted EBITDA and Adjusted EBITDA margin
(unaudited, in millions)
       
  Three Months Ended
September 30, 2026
  Twelve Months Ended
September 30, 2026
Net income (loss) attributable to Viper Energy, Inc.  $ 140     $ 276  
Net income (loss) attributable to non-controlling interest    160       324  
Net income (loss)    300       600  
Interest expense, net    30       117  
Non-cash share-based compensation expense    3       10  
Depreciation, depletion, and amortization    206       841  
Impairment    —       408  
Non-cash (gain) loss on derivative instruments    18       20  
Provision for (benefit from) income taxes    39       118  
Other non-cash or non-recurring expenses    —       12  
Adjusted EBITDA    596       2,126  
Less: Adjusted EBITDA attributable to non-controlling interest    284       1,030  
Adjusted EBITDA attributable to Viper Energy, Inc.  $ 312     $ 1,096  
       
Net income margin(1)   45 %     26 %
Adjusted EBITDA margin(1)   90 %     93 %

(1) Net income margin is calculated as net income (loss) divided by total operating income of $661 million for the three months ended September 30, 2026 and $2.28 billion for the twelve months ended September 30, 2026. Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total operating income.

OPERATING CASH FLOW BEFORE WORKING CAPITAL CHANGES, FREE CASH FLOW AND FREE CASH FLOW MARGIN

Operating cash flow before working capital changes, which is a non-GAAP financial measure, represents net cash provided by operating activities as determined under GAAP without regard to changes in operating assets and liabilities. The Company believes operating cash flow before working capital changes is a useful measure of the Company’s ability to generate cash to fund acquisition activities, service debt or pay dividends. The Company also uses this measure because changes in operating assets and liabilities relate to the timing of cash receipts and disbursements that the Company may not control and may not relate to the period in which the operating activities occurred.

The Company defines Free Cash Flow, which is a non-GAAP financial measure, as operating cash flow before working capital changes in excess of capital expenditures. The Company defines Free Cash Flow margin as Free Cash Flow divided by total operating income. The Company believes that Free Cash Flow and Free Cash Flow margin are useful to investors as they provide a measure to compare cash flow from operating activities across periods on a consistent basis. These measures should not be considered as alternatives to, or more meaningful than, net cash provided by operating activities as an indicator of liquidity. The Company’s computations of Free Cash Flow and Free Cash Flow margin may not be comparable to other similarly titled measures of other companies.

The following table presents a reconciliation of the GAAP financial measure of net cash provided by operating activities to the non-GAAP measure of operating cash flow before working capital changes and to the non-GAAP measure of Free Cash Flow and a reconciliation of the GAAP ratio of operating cash flow margin to the non-GAAP ratio of Free Cash Flow margin:

 
Viper Energy, Inc.
Operating cash flow before working capital changes, Free Cash Flow and Free Cash Flow margin
(unaudited, in millions)
   
  Three Months Ended
September 30, 2026
Net cash provided by operating activities  $ 447  
Changes in operating assets and liabilities    73  
Operating cash flow before working capital changes    520  
Less: Capital expenditures    —  
Free Cash Flow  $ 520  
   
Operating cash flow margin(1)    68 %
Free Cash Flow margin(1)    79 %

(1) Operating cash flow margin is calculated as net cash provided by operating activities divided by total operating income of $661 million. Free Cash Flow margin is calculated as Free Cash Flow divided by total operating income.

PRE-TAX INCOME ATTRIBUTABLE TO VIPER ENERGY, INC.

The following table presents a reconciliation of the GAAP financial measure of income (loss) before income taxes to the non-GAAP financial measure of pre-tax income attributable to the Company. Management believes this measure is useful to investors given it provides the basis for income taxes payable by the Company.

Viper Energy, Inc.
Pre-tax income attributable to Viper Energy, Inc.
(unaudited, in millions)
   
  Three Months Ended September 30, 2026
 
Income (loss) before income taxes  $ 339  
Less: Net income (loss) attributable to non-controlling interest    160  
Pre-tax income (loss) attributable to Viper Energy, Inc.  $ 179  
   
Income taxes payable by Viper Energy, Inc. for the current period  $ 49  
Effective cash tax rate attributable to Viper Energy, Inc.    27.4 %
       

NET DEBT

The Company defines the non-GAAP measure of net debt as debt (excluding debt issuance costs, discounts and premiums) less cash and cash equivalents. Net debt should not be considered an alternative to, or more meaningful than, total debt, the most directly comparable GAAP measure. Management uses net debt to determine the Company’s outstanding debt obligations that would not be readily satisfied by its cash and cash equivalents on hand. The Company believes this metric is useful to analysts and investors in determining the Company’s leverage position because the Company has the ability to, and may decide to, use a portion of its cash and cash equivalents to reduce debt.

  September 30, 2026   Net Q3 Principal Borrowings/
(Repayments)
  June 30, 2026   March 31, 2026   December 31, 2025   September 30, 2025
  (in millions)
Total debt(1)  $ 2,410     $ 715   $ 1,695     $ 1,620     $ 2,205     $ 2,640  
Cash and cash equivalents    (10 )         (77 )     (28 )     (13 )     (443 )
Net debt  $ 2,400         $ 1,618     $ 1,592     $ 2,192     $ 2,197  

(1) Excludes debt issuance costs, discounts & premiums.

DERIVATIVES

As of the date of this news release, the Company had the following outstanding derivative contracts. The Company’s derivative contracts are based upon reported settlement prices on commodity exchanges and published index prices. Crude oil derivative settlements are based on New York Mercantile Exchange (“NYMEX”) West Texas Intermediate (“WTI”) pricing and Crude Oil Brent pricing. Natural gas derivative settlements are based on NYMEX Henry Hub pricing and the regional natural gas pricing point indicated below. Basis swaps settle on the differential between the applicable benchmark price and the regional index price, and roll swaps settle on the differential between NYMEX WTI prompt-month and second-month contract prices. When aggregating multiple contracts, the weighted average contract price is disclosed.

   
  Q4 2026   Q1 2027   Q2 2027   Q3 2027   Q4 2027
Deferred Premium Puts – WTI (Cushing)   50,000       50,000       45,000       35,000       20,000  
Strike $ 50.00     $ 50.00     $ 50.00     $ 50.00     $ 50.00  
Premium $ (1.32 )   $ (1.36 )   $ (1.35 )   $ (1.35 )   $ (1.32 )
Deferred Premium Puts – WTI / Brent Basis   30,000       —       —       —       —  
Strike $ (45.00 )     —       —       —       —  
Premium $ (1.48 )     —       —       —       —  
Roll Swaps – WTI (Cushing)   15,000       —       —       —       —  
Swap Price $ 3.97       —       —       —       —  

       
    Q4 2026  
  Costless Collars – Henry Hub   60,000  
  Floor $ 2.75  
  Ceiling $ 6.64  

   
  Q4 2026   Q1 2027   Q2 2027   Q3 2027   Q4 2027
Natural Gas Basis Swaps – Waha Hub   80,000       50,000       50,000       50,000       50,000  
Swap Price $ (1.74 )   $ (1.40 )   $ (1.40 )   $ (1.40 )   $ (1.40 )
                                       

Investor Contact:

Chip Seale
+1 432.247.6218
cseale@viperenergy.com

Source: Viper Energy, Inc.; Diamondback Energy, Inc.

MIDLAND, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) —

Diamondback Stockholders,

This letter is meant to be a supplement to our earnings release and is being furnished to the Securities and Exchange Commission (SEC) and released to our stockholders simultaneously with our earnings release. Please see the information regarding forward-looking statements and non-GAAP financial information included at the end of this letter.

Mega Themes

Before we talk about the quarter, we would like to give you some insight into what we see as the mega-themes of the Permian Basin over the next decade, Diamondback’s potential role in those mega-themes and why our strategy will benefit Diamondback stockholders. In our mind, these three mega-themes are: increased recoveries of oil in place, gas production growth and monetization through LNG and power demand and the growing AI / power / infrastructure buildout in West Texas and the Permian Basin.

The past decade in the Permian Basin was dominated by capital efficiency improvements, resource expansion and consolidation. This resulted in more assets in the hands of larger, well-run operators turning the dream of the shale revolution into a reality, producing more consistent returns on and of capital to the stockholders that helped fund it.

While we expect to maintain consistent returns, we anticipate the next decade will look different. Upstream consolidation in the Permian will continue, albeit at a more measured pace given how much has already occurred to date. Capital efficiency will continue to improve, but the pace of above ground mechanical improvements will naturally slow relative to what has been accomplished over the last ten years. Resource expansion will continue and new zones like the Barnett and Woodford (more on that later) are exciting, but it will be tough to match the resource growth we saw from developing the Wolfcamp B as a standalone horizontal bench in 2012 in the Midland Basin to the 8+ zones we are developing today.

Therefore, we will need to do more with what we have, directly and indirectly. We will continue to improve our position by increasing working interest (and mineral interest at Viper Energy, Inc. (“Viper”), our consolidated mineral and royalty subsidiary), extending laterals through trades, grinding down costs and being prepared for M&A opportunities if or when they present themselves.

As we mentioned earlier, we are also working on being at the forefront of three Permian mega-themes:

1. Improving Recoveries

We currently estimate that we extract approximately 10% of the oil in place in the Permian Basin today. Every percentage point of incremental recovery carries significant value to our stockholders, and we are therefore very focused on improving recoveries. There are several factors that contribute to the ultimate recovery of hydrocarbons from a well, but the list below represents the main factors we are focused on.

a) Development design:
Each project Diamondback executes is designed to maximize the return the Company receives on capital while ensuring resource recovery is maximized at an appropriate incremental rate of return hurdle. Our philosophy has resulted in Diamondback’s projects generating the highest average returns relative to our peer group. These outcomes are clearly seen on slide #10 of this quarter’s investor presentation.

Broadly, our relatively higher wells per section × better per well performance ÷ the lowest cost structure in the basin = the maximum return for every dollar of capital invested. Diamondback was an early adopter of co-development in the Midland Basin, moving to this methodology in 2019 for the core zones from the Middle Spraberry to the Wolfcamp B. Co-development of 8+ benches in the Midland Basin, optimized spacing and targeting, longer laterals and creative wellbore trajectories allow us to optimize our developments while preserving the value of our remaining inventory – an advantage we believe is unmatched in the basin.

b) Completion design:
Proper completion sizing is imperative to maximizing value from each development project. The advancement of completion technology into simulfrac and continuous pumping are positive cost stories from an operational standpoint, but they have also allowed us to pursue more aggressive stage designs with tighter cluster and stage spacing to increase reservoir contact and near-wellbore fracture complexity. We believe this, combined with our efforts around advanced chemical additives, is contributing to recent well outperformance relative to previous vintages seen on slide #10 of this quarter’s investor presentation.

c) Enhanced Oil Recovery (“EOR”):
Chemical EOR has the potential to meaningfully improve recovery factors and shallow base decline rates in unconventional reservoirs. Shallowing our corporate base decline by just 1% at current capital efficiency implies drilling 10 to 15 fewer wells to maintain flat oil production, extending inventory quality and duration.

Chemical EOR makes it easier for oil to flow through the reservoir to the wellbore. We have several ongoing pilots testing various surfactant designs both in the remedial and completion phases of our operations. These pilots are in the early stages, and we have seen a wide range of outcomes from our initial tests. We will continue to learn from these tests and refine our methodologies to continuously improve, just as we did on the completion side of the business over the last fifteen years.

Our goal is and has always been to be the best at converting rock into cash flow. We have demonstrated this ability consistently over the past decade and will continue to do so moving forward. We are confident the technologies and workflows we are developing today will propel us to higher recoveries in the future and we look forward to keeping our stockholders updated on our progress.

2. Gas Production and Monetization

In the third quarter, future gas growth out of the Permian Basin received significant attention as a WhiteWater-led consortium (that includes Diamondback) reached Final Investment Decision (“FID”) on another large diameter pipeline out of the basin. This pipe is called Solitude and is set to enter service in the second half of 2029. This project consists of two twin 48″ lines able to move 4.5 bcf/d out of the Permian to Katy and Gulf Coast markets, with potential to expand to 7.5 bcf/d. While the market was surprised that another pipe reached FID this quickly after multiple announcements over the last 18 months, we were not.

As we have said many times, the Permian Basin has not tried to produce gas yet. We expect the Permian to be the largest natural gas play as well as the largest oil play in the United States in the 2030s. Gas to oil ratios will naturally continue to expand, secondary zones in both the Midland and the Delaware Basins are gassier than what operators have targeted to date and there are gas-weighted exploratory zones that have not even been tested yet given the perpetual egress issues out of this basin.

As for Diamondback’s strategy, our goal is to continue to control more of our gas further downstream to a mix of end markets, primarily feeding the Gulf Coast LNG complex. We are working to build relationships with LNG players who are long offtake and short physical molecules. There should be beneficial deals to get done with those companies in the coming years. We also believe in-basin and in-state power demand will continue to grow, driven by both behind-the-meter power development and the expansion of the Texas grid.

At the highest level, the gas theme in the Permian Basin has moved from supply-push to demand-pull, which should be beneficial to the owners of the molecule long-term and therefore Diamondback stockholders.

3. West Texas AI / Power / Infrastructure Buildout

We believe that the incremental large-scale data center development in the United States should go through West Texas and that Diamondback can be an integral part of that value chain without overstepping our core competencies. In our mind, our Company owns or has access to all the key components of data center development:

  • Fuel: We have significant natural gas reserves that we control. These can grow if needed.
  • Land: We own surface in areas conducive to development and know how to strategically grow our position.
  • Water: We are invested in and understand the water business, which is vital to our upstream business and becoming increasingly important as industrial use cases including data center and power cooling needs grow.
  • Deal Execution: We have a long track record of sourcing, structuring, financing and integrating transactions across our value chain. Since our 2012 IPO, Diamondback, along with Viper, have successfully completed approximately $60 billion in trades across dozens of transactions, and in parallel, have formed, scaled and successfully exited joint ventures in midstream and water infrastructure, creating value beyond the drillbit. In short, we know how to get deals done, upstream and non-upstream alike, that benefit our stockholders.

Therefore, we believe companies like Diamondback with credible projects will continue to rise to the top. Our hope is to build relationships and partnerships across this space that put us in the middle of the AI revolution, and we think a company like ours can add significant value to advancing this mega-theme.

We have already developed significant relationships with strong, reliable partners in working our first project. We expect these partnerships to grow, but also see room for more. West Texas has a significant amount of private land, an abundance of fuel for power and our industry (Diamondback in particular) knows how to build things with unmatched efficiency. Diamondback’s own production has grown more than 330x since 2012 – a growth rate competitive with the tech industry that is naturally intersecting with ours.

Barnett / Woodford Update

We received significant market curiosity after revealing our Barnett position in the Midland Basin earlier this year. Since that announcement, we have grown our position to 224,000 net acres, up 12% since February. We are also entering a period of increased activity in the play as we move to full-field development so we can maximize capital efficiency while honoring lease obligations.

When we revealed our position, we told our investors we needed to work the well costs down to $800 per lateral foot for the play to be competitive with our core program. We are on our way to this number, with drilling costs down over 10% per lateral foot year-to-date including a recent well below $350 per lateral foot. Completion costs have also been reduced to below $400 per lateral foot as we have moved to large pad simulfrac operations on most current and future Barnett projects.

Recent well results also continue to increase our excitement about the Barnett. Today we revealed data around our best wells in the play on slide #11 of this quarter’s investor presentation, which had previously remained private as we worked through our leasing program. This performance, combined with our improving cost structure, further strengthens our conviction in this emerging opportunity.

Governance

In September, we disclosed an agreement with our largest stockholder, SGF FANG Holdings, LP (“SGF”), to revise the stepdown thresholds for SGF’s board designation rights. In connection with SGF’s most recent stock sale that reduced its ownership below 25% and reduced its corresponding right to designate board members from four board members to two board members, we essentially agreed that SGF could continue to designate two board members for so long as it owns at least 10% of our outstanding stock.

The Diamondback Board now has 11 members, in line with S&P 500 and large-cap energy peer averages. We believe this size balances breadth of expertise with cohesion. While we have two Board members who are SGF designees and nine who are not, we feel we are one Diamondback Board with a unified strategy to drive stockholder value while ensuring our largest stockholder feels appropriately represented on the Board with two well-qualified members who collectively bring over 75 years of experience in the oil and gas industry. We believe this is best-in-class governance.

Macro Update

The macro backdrop is almost exactly as we described last quarter: highly volatile and impossible to predict. The timing of the eventual global oil supply normalization is anyone’s guess, and we therefore expect the current volatility to continue. Through this volatility, our priorities remain unchanged: execute with the best capital efficiency in the industry and allocate Free Cash Flow appropriately to maximize long-term stockholder value.

Third Quarter 2026 Operational Performance

Third quarter oil production averaged 525 MBO/d, flat with the second quarter and above the midpoint of our guidance range. Total production for the quarter averaged 1,034 MBOE/d, up 2% quarter over quarter. Third quarter cash capital expenditures were $1.03 billion, within our $950 million to $1.05 billion guidance range. With one quarter remaining, we have updated our full-year 2026 oil production guidance to ~524 MBO/d, total production guidance to ~1,015 MBOE/d; and our full-year capex guidance to approximately $3.95 billion to $4.00 billion.

Fourth quarter guidance is 518 to 528 MBO/d (1,025 to 1,045 MBOE/d) on $1.00 to $1.05 billion of capex. Our current expectation for activity in 2027 is to run five electric simulfrac fleets consistently for maximum efficiency while running enough rigs ahead of those crews to maintain the execution buffers one would expect from Diamondback.

On the drilling side, our blended cost per lateral foot rose in the quarter as the program shifted toward deeper Barnett and Wolfcamp D targets, which now make up roughly a fifth of the wells we drill. On a like-for-like basis, drilling costs per foot in each formation remain flat to lower than a year ago. In total, we drilled 105 gross wells and completed 135, with average completed lateral length up roughly 13% quarter over quarter to 13,584 feet per well. Our completion crews finished 1.86 million lateral feet, 10% more than last quarter, at a cost per lateral foot essentially flat with both the prior quarter and a year ago. These results absorbed higher diesel, sand and water costs, consistent with the inflation pressure we flagged last quarter in casing, fuel and fuel-adjacent items. Service pricing outside those categories has remained largely stable, but it is logical that inflation could build if oil prices stay in the triple digits and the Permian rig count keeps rising. We expect any increase to be more modest than the 2022 upcycle, when rig activity surged while supply chains were still recovering from the pandemic. We continue to challenge our teams to offset cost pressure with efficiency gains in the field; we expect those gains to materialize, but the net effect will depend on the macro environment.

Technology is increasingly part of how we deliver these results. Artificial intelligence continues to grow in importance to our daily operations. We now have ~500 plunger-lift wells, about a third of our current count, that run autonomously, and we expect to convert the remainder in short order. We are also in the early stages of integrating drones into our field operations where the drones can identify issues ahead of human interaction, improving human efficiency and reducing corporate downtime.

These gains are visible in our unit costs. Lease operating expense was $5.97 per BOE, flat with the second quarter and roughly 4% below the first quarter, and total cash operating expense was $10.91 per BOE, down slightly from $10.96 in the second quarter and about 3% below the first quarter. Behind those numbers is a production organization doing more work at lower unit cost: our well-maintenance teams completed 1,448 jobs, 19% more than in the second quarter, at an average cost per job roughly 10% lower. Additionally, electric submersible pump repair costs are 14% less on average. Keeping downtime and the workover backlog in check as our well count grows is what is holding lifting cost down.

Third Quarter 2026 Financial Performance

We generated $2.6 billion in net cash provided by operating activities in the third quarter, which translated to $2.1 billion of Free Cash Flow. Cash capital expenditures of $1.0 billion represented 39% of net cash provided by operating activities for the quarter and 37% year to date. Our corporate reinvestment ratio (defined as cash CAPEX divided by Operating Cash Flow Before Working Capital Changes) was 32% for both the quarter and year to date, meaning two of every three dollars of cash flow we generated this year have been converted to Free Cash Flow.

Since the Endeavor merger closed eight quarters ago, oil production per share has increased every quarter and is up 15% over that span. Year over year, oil production per share has grown 7.5% on absolute oil growth of 4%. Year over year, net cash provided by operating activities per share has grown 12.5%, and Free Cash Flow per share has grown 26%, with our diluted share count down 3%.

Capital Allocation

Earlier this year, we removed our commitment to return a minimum amount of Free Cash Flow on a quarterly basis to stockholders. Since then, we have focused on taking advantage of what the market gives us. We have repurchased $1.1 billion of notional bonds outstanding for ~$970 million (including accrued interest) this year. It is rare for an E&P to be able to do this pro-cyclically. On top of that, in 2026 through September 30, we have reduced total debt at Diamondback (excluding Viper) by approximately $1.5 billion, to $11.0 billion, and net debt at Diamondback by approximately $2.0 billion. On a consolidated basis, total debt has decreased approximately $1.3 billion and net debt approximately $1.7 billion this year through September 30.

“Ground game” has been a hot topic in the Permian Basin this year, and Diamondback has always prided itself on executing deals of all sizes. Year to date, we have executed 34 acquisitions for $406 million, adding over 28,000 net acres and 95 net locations, and closed 10 trades covering more than 20,000 net acres. While each deal is small relative to our enterprise, in aggregate they matter: this year’s ground game activity has added 1.9 million lateral feet to inventory, replacing roughly a full quarter’s worth of completed footage. Every one of these deals creates value for our stockholders through higher working interest, longer laterals and extended inventory duration – little wins that add up year in and year out.

We also saw periods of stock price weakness in the third and early fourth quarters, and we took advantage of this weakness and bought back 1.7 million shares at an average price of $186.11. As we continue to generate cash flow at what we believe are above mid-cycle commodity prices, the “top” that we use to ensure we buy back stock at an accretive value relative to mid-cycle commodity pricing and our cost of capital will continue to go up – accreting value to the stockholders long-term. On the other hand, we are also preparing our balance sheet to be able to be aggressive on stock repurchases at the appropriate time of the natural commodity cycle.

Lastly, today we announced we increased our base dividend by over 7% to $4.72 per share annually from $4.40 previously. As a reminder, base dividend growth remains a core tenet of the value proposition at Diamondback and our base dividend is now up over 9x since initiating at $0.50 per share in 2018.

In closing, we continue to execute exceptionally well on the base business. This execution and the trust we have in our team frees us up to think more strategically about the future of the Permian Basin and Diamondback’s role in that future. We gave you a glimpse into that thinking today, see exciting things on the horizon and will update our stockholders as we progress on these initiatives with the transparency you should continue to expect from us.

Thank you for your continued interest in Diamondback Energy.

Sincerely,

Kaes Van’t Hof
Chief Executive Officer and Director

Investor Contact:
Adam Lawlis
+1 432.221.7467
alawlis@diamondbackenergy.com 

Forward-Looking Statements:

This letter contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, including statements regarding Diamondback’s: future performance; business strategy; future operations (including drilling plans and capital plans); estimates and projections of revenues, losses, costs, expenses, returns, cash flow, and financial position; reserve estimates and its ability to replace or increase reserves; anticipated benefits or other effects of strategic transactions (including the 2026 drop down to Diamondback’s subsidiary, Viper Energy, Inc. (“Viper”), Viper’s Riverbend acquisition, Viper’s McElroy Ranch acquisition and Viper’s Sitio acquisition, and other acquisitions, divestitures or reorganizations); and plans and objectives of management (including plans for future cash flow from operations and for executing environmental strategies) are forward-looking statements. When used in this letter, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) as they relate to Diamondback are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Diamondback believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond Diamondback’s control. Accordingly, forward-looking statements are not guarantees of future performance and Diamondback’s actual outcomes could differ materially from what Diamondback has expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: geopolitics and market conditions, including changes in supply and demand levels for oil, natural gas and natural gas liquids and the resulting impact on the price for those commodities; changes in U.S. energy, environmental, monetary and trade policies, including with respect to tariffs or other trade barriers and any resulting trade tensions; actions taken by the members of OPEC and its non-OPEC allies (OPEC+) affecting the production and pricing of oil, as well as other domestic and global political, economic, or diplomatic developments; changes in general economic, business or industry conditions, including changes in foreign currency exchange rates, interest rates, inflation rates, and instability in the financial sector; regional supply and demand factors, including delays, curtailments or interruptions of production, or governmental orders, rules or regulations that impose production limits; federal and state legislative and regulatory initiatives relating to hydraulic fracturing, including the effect of existing and future laws and governmental regulations; physical and transition risks relating to climate change, changing political and social perspectives on climate change and other environmental, social and governance factors, and risks from our publicly disclosed targets related to sustainability and emissions reduction initiatives; challenges in developing our existing leasehold acreage and finding, developing or acquiring additional reserves; restrictions on the use of water, including limits on the use of produced water and a moratorium on new produced water disposal well permits recently imposed by the Texas Railroad Commission in an effort to control induced seismicity in the Permian Basin; significant declines in prices for oil, natural gas, or natural gas liquids, which could require recognition of significant impairment charges; conditions in the capital, financial and credit markets, including the availability and pricing of capital for acquisitions, exploration and development operations; challenges with employee retention and an increasingly competitive labor market; changes in availability or cost of rigs, equipment, raw materials, supplies and oilfield services; changes in safety, health, environmental, tax and other regulations or requirements (including those addressing air emissions, water management, or the impact of global climate change); security threats, including cybersecurity threats and disruptions to our business and operations from breaches of our information technology systems, or from breaches of information technology systems of third parties with whom we transact business; lack of, or disruption in, access to adequate and reliable electrical power, internet and telecommunication infrastructure, information and computer systems, transportation, processing, storage and other facilities for our oil, natural gas and natural gas liquids; failures or delays in achieving expected reserve or production levels from existing and future oil and natural gas developments, including due to operating hazards, drilling risks, or the inherent uncertainties in predicting reserve and reservoir performance; inability to keep pace with technological developments in our industry; failure to meet our obligations under our oil purchase contracts; loss of one or more customers or their inability to meet their obligations; geographical concentration of our primary operations; risks from our return of capital activity, and uncertainties over our future dividends and share repurchases; difficulty in obtaining necessary approvals and permits; severe weather conditions and natural disasters; changes in the financial strength of counterparties to our credit facilities and hedging contracts; our substantial indebtedness and restrictions to our operating and financial flexibility; changes in our credit rating; failure to identify, complete and successfully integrate acquisitions, including Viper’s Riverbend acquisition, McElroy Ranch acquisition and Sitio acquisition; the Endeavor stockholders’ ability to significantly influence our business and potential conflicts of interest; and other risks described in Part I, Item 1A of Diamondback’s Annual Report on Form 10-K, filed with the SEC on February 25, 2026, and those risks disclosed in its subsequent filings on Forms 10-Q and 8-K, which can be obtained free of charge on the SEC’s website at http://www.sec.gov and Diamondback’s website at www.diamondbackenergy.com/investors.

In light of these factors, the events anticipated by Diamondback’s forward-looking statements may not occur at the time anticipated or at all. Moreover, Diamondback operates in a very competitive and rapidly changing environment and new risks emerge from time to time. Diamondback cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements. All forward-looking statements speak only as of the date of this letter or, if earlier, as of the date they were made. Diamondback does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

Non-GAAP Financial Measures

This letter includes financial information not prepared in conformity with generally accepted accounting principles (GAAP), such as Free Cash Flow, Free Cash Flow per share, Operating Cash Flow Before Working Capital Changes, and net debt. The non-GAAP information should be considered by the reader in addition to, but not instead of, financial information prepared in accordance with GAAP. A reconciliation of the differences between these non-GAAP financial measures and the most directly comparable GAAP financial measures can be found in Diamondback’s quarterly results, which are posted on Diamondback’s website at www.diamondbackenergy.com/investors and included as Exhibit 99.1 to the Current Report on Form 8-K filed by Diamondback with the SEC that also includes this letter as Exhibit 99.2. Furthermore, this letter includes or references certain forward-looking, non-GAAP financial measures. Because Diamondback provides these measures on a forward-looking basis, it cannot reliably or reasonably predict certain of the necessary components of the most directly comparable forward-looking GAAP financial measures, such as future impairments and future changes in working capital. Accordingly, Diamondback is unable to present a quantitative reconciliation of such forward-looking, non-GAAP financial measures to the respective most directly comparable forward-looking GAAP financial measures. Diamondback believes that these forward-looking, non-GAAP measures may be a useful tool for the investment community in comparing Diamondback’s forecasted financial performance to the forecasted financial performance of other companies in the industry.

CHATTANOOGA, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) — Astec Industries, Inc. (NASDAQ: ASTE) announced that its Board of Directors declared a quarterly dividend of $0.13 per share. The dividend is to be paid on or about December 4, 2026, to shareholders of record as of the close of business on November 16, 2026.

About Astec

Astec, (www.astecindustries.com), is a manufacturer of specialized equipment for asphalt road building, aggregate processing and concrete production. Astec’s manufacturing operations are divided into two primary business segments: Infrastructure Solutions that includes road building, asphalt and concrete plants, thermal and storage solutions; and Materials Solutions that include our aggregate processing equipment. Astec also operates a line of controls and automation products designed to deliver enhanced productivity through improved equipment performance.

For more information, visit astecindustries.com and follow us on social media.

LinkedIn https://www.linkedin.com/company/astecindustries/
Facebook https://www.facebook.com/astecindustries
Instagram https://www.instagram.com/astec_industries/
YouTube https://www.youtube.com/@astec6306/featured
Twitter @astecindustries

Contact:

Stephen C. Anderson
Senior Vice President, Investor Relations
sanderson@astecindustries.com
+1 (423) 899-5898
www.astecindustries.com

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 –

– CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years of age and older –

– FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310® for severe hypertriglyceridemia and elevated LDL-C –

– Phase 1b data for CTX310 in severe hypertriglyceridemia to be presented in a late-breaking oral presentation at AHA Scientific Sessions 2026; Phase 1 data for zugo-cel in systemic sclerosis to be presented at ACR Convergence 2026 –

– Completed enrollment in the Phase 2 clinical trial of CTX611 in patients undergoing total knee arthroplasty –

– Appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer and A.J. Silver as Chief Financial Officer –

ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the third quarter ended September 30, 2026.

“The third quarter marked meaningful progress for CRISPR Therapeutics,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “CASGEVY is reaching more patients, including younger children following new approvals in the U.K. and the Middle East, and the FDA’s RMAT designations for CTX310 underscore its potential to address significant unmet needs in cardiovascular disease. With new clinical data from CTX310 and zugo-cel in the coming weeks and enrollment complete in our Phase 2 trial of CTX611, we are entering a pivotal period for our pipeline.”

Recent Highlights and Outlook

Hemoglobinopathies and CASGEVY® (exagamglogene autotemcel)

  • CASGEVY, the world’s first approved CRISPR-based therapy, has been shown to reduce or eliminate vaso-occlusive crises (VOCs) in eligible patients with sickle cell disease (SCD) and transfusion requirements in eligible patients with transfusion-dependent beta thalassemia (TDT). CASGEVY is approved in 39 countries across North America, Europe, and the Middle East for eligible patients 12 years of age and older, with approvals for younger children in five of those countries.
  • CASGEVY generated third quarter 2026 revenue of $99 million, representing 30% growth quarter-over-quarter and nearly six times the revenue reported in the third quarter of 2025. Twice as many in the first nine months of 2026 as in all of 2025, and more than 750 patients have initiated treatment worldwide.
  • CASGEVY’s availability for younger patients continues to expand. In July, the FDA approved CASGEVY for children 2 years of age and older with SCD or TDT, making it the first genetic therapy for SCD and TDT approved for this age group, and multiple children have since initiated treatment in the U.S. The Kingdom of Saudi Arabia, the United Arab Emirates, and the Kingdom of Bahrain have also approved CASGEVY for children 2 years of age and older, and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved CASGEVY for children 5 years of age and older with severe SCD or TDT.
  • Building on CASGEVY, CRISPR Therapeutics is advancing an in vivo hematopoietic stem cell editing approach that could extend gene editing to many more patients with SCD and TDT. Using lipid nanoparticle (LNP)-mediated delivery, the approach is designed to edit stem cells directly in the body, potentially simplifying treatment and broadening global access.

In Vivo Liver Editing

CRISPR Therapeutics continues to advance a diversified portfolio of in vivo gene editing programs leveraging its proprietary liver-directed LNP delivery platform.

  • The Phase 1 clinical trial of CTX310®, targeting angiopoietin-related protein 3 (ANGPTL3) is ongoing.
  • CRISPR Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for the treatment of severe hypertriglyceridemia (sHTG) and for the treatment of patients with elevated LDL-C. RMAT designation provides the benefits of Fast Track and Breakthrough Therapy designations, including early interactions with the FDA and potential eligibility for priority review and accelerated approval.
  • In August, CRISPR Therapeutics presented Phase 1a durability data for CTX310 in a late-breaking session at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in The New England Journal of Medicine. A single course treatment of CTX310 produced deep and durable reductions in circulating ANGPTL3, triglycerides (TG), and low-density lipoprotein (LDL) that were sustained through one year of follow-up. At the highest dose, the mean reductions from baseline were 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL-C in a mixed patient cohort with high triglycerides, high LDL-C, or both. CTX310 was well tolerated with no treatment-related serious adverse events.
  • Phase 1b data in patients with sHTG will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026 on November 9, 2026, at 8:00 a.m. CT. 
  • The Phase 1 clinical trial of CTX340™, targeting angiotensinogen (AGT), in patients with refractory hypertension is ongoing.
  • The Phase 1 clinical trial of CTX460™, targeting SERPINA1 for alpha-1 antitrypsin deficiency (AATD), is ongoing. CTX460 is the first investigational candidate from the Company’s SyNTase™ editing platform.
  • CTX321™, the Company’s next-generation LPA program, is progressing through IND/CTA-enabling studies.

siRNA-based Programs

CRISPR Therapeutics’ small interfering RNA (siRNA)-based portfolio, developed in collaboration with Sirius Therapeutics, includes programs targeting cardiovascular and thromboembolic diseases.

  • CRISPR Therapeutics has completed enrollment in the Phase 2 clinical trial of CTX611 (SRSD107), a long-acting siRNA therapeutic targeting Factor XI (FXI), in patients undergoing total knee arthroplasty (TKA), with an update expected in the second half of 2026. CTX611 has potential across a broad range of thromboembolic indications. CRISPR Therapeutics will lead global Phase 3 development, with Sirius Therapeutics overseeing development in greater China.
  • CRISPR Therapeutics has the option to nominate up to two additional siRNA targets, with an update expected in 2027.

Autoimmune Disease and Immuno-Oncology

Zugocabtagene geleucel (zugo-cel; formerly CTX112™) continues to advance across both autoimmune disease and hematologic malignancies.

  • In autoimmune disease, zugo-cel is being evaluated in three ongoing Phase 1 trials: a rheumatology basket including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM); a hematology basket in immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA); and a trial in autoimmune neurologic diseases, including progressive multiple sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), N-methyl-D-aspartate receptor (NMDAR) and leucine-rich glioma-inactivated protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff person syndrome (SPS). Enrollment is ongoing globally.
  • Phase 1 clinical data in patients with refractory SSc will be presented in a poster presentation at the American College of Rheumatology (ACR) Convergence 2026 on November 8 at 10:30 a.m. ET.
  • In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell malignancies is ongoing, with updates anticipated in the second half of 2026. A combination study evaluating zugo-cel with pirtobrutinib in aggressive B-cell lymphomas, under the Company’s existing collaboration with Lilly, is also ongoing.

CRISPR Therapeutics is also advancing a proprietary in vivo CAR-T platform with potential applications across autoimmune disease and oncology.

The Company is pursuing two modalities, supported by an antibody-conjugated LNP delivery system targeting immune cells: a transient, re-dosable mRNA-based CAR-T and a non-viral, integrating CAR-T, for which the Company is evaluating multiple integration approaches. Both programs are in the IND/CTA-enabling phase, focused on a best-in-class profile.

Regenerative Medicine

  • The Company is developing CTX213™, a deviceless beta cell replacement candidate for Type 1 diabetes, consisting of unencapsulated precursor islet cells derived from edited induced pluripotent stem cells (iPSCs). CTX213 has demonstrated compelling preclinical efficacy through direct administration and is progressing toward the clinic.

Other Corporate Matters

  • Earlier today, CRISPR Therapeutics announced the appointment of Sivakesava Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings more than 30 years of technical operations and quality leadership across biologics, vaccines, oligonucleotides, RNA therapeutics, and LNP delivery, most recently as Chief Technical Officer at Orna Therapeutics.
  • In October, CRISPR Therapeutics announced the appointment of A.J. Silver, the Company’s Senior Vice President of Finance, as Chief Financial Officer, effective October 19, 2026, succeeding Raju Prasad, Ph.D., who stepped down to pursue external opportunities.
  • The Company’s in vivo and cell therapy programs are supported by a wholly-owned GMP manufacturing facility in Framingham, Massachusetts. The facility provides end-to-end production capabilities, supports both clinical and future commercial supply, and enables an industry-leading cost of goods.

Third Quarter 2026 Financial Results  

  • Cash Position: Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026, compared to $1,975.8 million as of December 31, 2025. The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses.
  • R&D Expenses: R&D expenses were $71.9 million for the third quarter of 2026, compared to $58.9 million for the third quarter of 2025. The increase in R&D expense was primarily attributable to an increase in external research and development expenses and sublicense fees, offset by a decrease in employee-related costs.
  • Acquired In-Process R&D Expenses: Acquired in-process R&D expenses were $11.7 million for the third quarter of 2026. Acquired in-process R&D expenses for the third quarter of 2026 primarily consisted of a development milestone under the Sirius Agreement that was recognized in the third quarter of 2026. No acquired in-process R&D expenses were recognized during the third quarter of 2025.
  • G&A Expenses: General and administrative expenses were $17.9 million for the third quarter of 2026, compared to $16.9 million for the third quarter of 2025.
  • Collaboration Expense: Collaboration expense, net, was $41.3 million for the third quarter of 2026, compared to $57.1 million for the third quarter of 2025. The decrease was primarily attributable to an increase in the Company’s share of CASGEVY revenue.
  • Net Loss: Net loss was $111.4 million for the third quarter of 2026, compared to a net loss of $106.4 million for the third quarter of 2025.

About CASGEVY® (exagamglogene autotemcel [exa-cel])

CASGEVY® is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy for eligible patients with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT), in which a patient’s own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate VOCs for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world, and for younger children in select countries.

About the CRISPR Therapeutics – Vertex Collaboration for CASGEVY

CRISPR Therapeutics and Vertex established a strategic research collaboration in 2015 to discover and develop therapies leveraging CRISPR/Cas9 technology to address the underlying genetic causes of human disease. CASGEVY is the first approved therapy to emerge from this collaboration. Under an amended agreement, Vertex leads global development, manufacturing, and commercialization of CASGEVY, and Vertex and CRISPR Therapeutics share profits and program costs on a 60/40 basis. Vertex is the manufacturer and exclusive license holder of CASGEVY.

About In Vivo Liver Editing Programs

CRISPR Therapeutics has established a proprietary lipid nanoparticle (LNP) delivery platform to enable gene editing in the liver using both CRISPR/Cas9 and its novel, proprietary SyNTase™ editing technology. The Company’s in vivo portfolio includes three cardiovascular programs: CTX310, targeting angiopoietin-related protein 3 (ANGPTL3), in development for heterozygous and homozygous familial hypercholesterolemia, mixed dyslipidemias, and severe hypertriglyceridemia; CTX340, targeting angiotensinogen (AGT), in development for refractory hypertension; and CTX321, targeting LPA, in development for patients with elevated lipoprotein(a) [Lp(a)]. In addition, the Company’s disclosed development candidates also include CTX460™, targeting SERPINA1 using SyNTase editing, for the treatment of alpha-1 antitrypsin deficiency (AATD).

About CTX611 (SRSD107)

CTX611 is a novel double-stranded, long-acting siRNA, designed to target the human coagulation factor XI, or FXI, messenger RNA and inhibit FXI protein expression. Through modulation of the intrinsic coagulation pathway, CTX611 is intended to provide anticoagulant and antithrombotic effects with a decreased risk of bleeding compared to other anti-thrombotics. Supported by clinical experience conducted by Sirius Therapeutics in two Phase 1 clinical trials, the Company and Sirius Therapeutics are developing CTX611 as a long-acting FXI inhibitor with the potential to support infrequent, including semi-annual, subcutaneous administration.

About the CRISPR Therapeutics – Sirius Therapeutics Collaboration for siRNA

CRISPR Therapeutics and Sirius Therapeutics entered into a strategic collaboration in 2025 to develop and commercialize siRNA therapies for thromboembolic disorders and other serious diseases. The lead program, CTX611, is a long-acting siRNA targeting FXI, which the companies will co-develop on an equal cost-and-profit-sharing basis. CRISPR Therapeutics will lead commercialization in the U.S., while Sirius will lead commercialization in greater China. The collaboration also provides CRISPR Therapeutics with the option to license up to two additional siRNA programs.

About Zugocabtagene Geleucel (zugo-cel; formerly CTX112)

Zugocabtagene geleucel (zugo-cel) is a wholly-owned, allogeneic chimeric antigen receptor (CAR) T cell therapy product candidate targeting Cluster of Differentiation 19 (CD19), in development for both autoimmune and immuno-oncology indications. The off-the-shelf therapy leverages CRISPR/Cas9 for targeted gene knockout and CAR insertion, enabling immune evasion and enhanced T effector cell potency, and is administered following a standard lymphodepletion regimen without the need for human leukocyte antigen (HLA) matching. In autoimmune disease, zugo-cel is being investigated in three ongoing basket trials. The rheumatology basket trial is enrolling adult patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory myositis (IM). The hematology basket trial is enrolling patients with immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA). The neuroimmune basket trial is enrolling patients with progressive multiple sclerosis (PMS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated Disease (MOGAD), N-methyl-D-aspartate receptor (NMDAR) and leucine-rich glioma-inactivated Protein 1 (LGI1) autoimmune encephalitis (AIE), and stiff person syndrome (SPS). In immuno-oncology, zugo-cel is being investigated in a trial in adult patients with relapsed or refractory B-cell malignancies.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

CRISPR THERAPEUTICS® standard character mark and design logo, CTX112™, CTX213™, CTX310®, CTX321™, CTX340™, CTX460™, CTX611™ and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners.

CRISPR Special Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements made by Dr. Kulkarni in this press release, as well as regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) data included in this press release, as well as the ability to use data from ongoing and planned studies and clinical trials for the design and initiation of further studies and clinical trials; (iii) CRISPR Therapeutics strategy, goals, anticipated financial performance and the sufficiency of its cash resources; (iv) plans and expectations for the commercialization of and anticipated benefits of CASGEVY, including anticipated patient access to CASGEVY; (v) regulatory submissions and authorizations, including timelines for and expectations regarding regulatory agency decisions; (vi) the expected benefits of its collaborations; and (vii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9 and SyNTase, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

This press release also contains information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from market research firms and other third parties, including medical publications, government data and similar sources. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. This press release discusses investigational therapies and is not intended to convey conclusions about efficacy or safety as to those investigational therapies or uses of such investigational therapies. There is no guarantee that any investigational therapy will successfully complete clinical development or gain approval from applicable regulatory authorities.

Investor Contact:
+1-617-307-7503
ir@crisprtx.com

Media Contact:
+1-617-315-4493
media@crisprtx.com

             
CRISPR Therapeutics AG
Condensed Consolidated Statements of Operations
(Unaudited, In thousands except share data and per share data)
 
             
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
Revenue:                        
Collaboration revenue   $ 12,323     $ —     $ 23,323     $ —  
Grant revenue     346       889       985       2,646  
Total revenue     12,669       889       24,308       2,646  
Operating expenses:                        
Research and development     71,888       58,902       207,614       201,280  
Acquired in-process research and development     11,675       —       14,148       96,253  
General and administrative     17,867       16,931       52,603       55,143  
Collaboration expense, net     41,284       57,115       127,505       159,777  
Total operating expenses     142,714       132,948       401,870       512,453  
Loss from operations     (130,045 )     (132,059 )     (377,562 )     (509,807 )
Total other income, net     18,682       26,237       53,913       61,841  
Net loss before income taxes     (111,363 )     (105,822 )     (323,649 )     (447,966 )
Provision for income taxes     (74 )     (619 )     (1,873 )     (3,020 )
Net loss     (111,437 )     (106,441 )     (325,522 )     (450,986 )
Foreign currency translation adjustment     2       (28 )     (20 )     94  
Unrealized (loss) gain on marketable securities     (9,456 )     973       (18,884 )     3,052  
Comprehensive loss   $ (120,891 )   $ (105,496 )   $ (344,426 )   $ (447,840 )
Net loss per common share — basic   $ (1.15 )   $ (1.17 )   $ (3.38 )   $ (5.12 )
Basic weighted-average common shares outstanding     96,741,070       91,305,337       96,437,995       88,124,241  
Net loss per common share — diluted   $ (1.15 )   $ (1.17 )   $ (3.38 )   $ (5.12 )
Diluted weighted-average common shares outstanding     96,741,070       91,305,337       96,437,995       88,124,241  

       
CRISPR Therapeutics AG
Condensed Consolidated Balance Sheets Data
(Unaudited, in thousands)
       
    As of  
    September 30, 2026     December 31, 2025  
Cash and cash equivalents   $ 192,027     $ 347,559  
Marketable securities     2,080,521       1,628,269  
Marketable securities – non-current     4,021       —  
Working capital     2,144,117       1,836,551  
Total assets     2,556,412       2,265,243  
Total shareholders’ equity     1,648,068       1,921,813  

MIDLAND, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Diamondback Energy, Inc. (NASDAQ: FANG) (“Diamondback,” “we,” “our” or the “Company”) today announced financial and operating results for the third quarter ended September 30, 2026.

THIRD QUARTER 2026 HIGHLIGHTS

  • Average oil production of 525 MBO/d (1,034 MBOE/d)
  • Net cash provided by operating activities of $2.6 billion; Operating Cash Flow Before Working Capital Changes1 of $3.2 billion
  • Cash capital expenditures of $1.0 billion
  • Free Cash Flow1 and Adjusted Free Cash Flow1 of $2.1 billion and $2.2 billion, respectively
  • Increased annual base dividend by 7.3% to $4.72 per share; marks an 18% year over year increase and a ~2.2% annualized yield2
  • Repurchased 1.3 million shares of common stock for approximately $251 million
  • Repurchased $106 million in aggregate principal amount of 2054 and 2064 Senior Notes at a weighted average price of 94.9% of par ($103 million, including accrued interest)
  • Acquired a 7.5% equity interest in the Solitude Pipeline System, a Permian-to-Katy natural gas pipeline

____________________________________
1 NON-GAAP DISCLOSURES – For a definition of Operating Cash Flow Before Working Capital Changes, Free Cash Flow, Adjusted Free Cash Flow, Adjusted Net Income, Adjusted EBITDA, Adjusted Net Income per Diluted Share, Net Debt and reconciliations of such non-GAAP financial metrics to their respective most directly comparable GAAP metrics, please see “Non-GAAP Financial Measures” below.
2 Cash dividend payable on November 19, 2026; annualized yield based on October 30, 2026 closing share price of $212.08

UPDATED 2026 GUIDANCE HIGHLIGHTS

  • Increasing annual oil production guidance to ~524 (from 522+) MBO/d with total BOE production of ~1,015 (from 1,000+) MBOE/d and full year cash capital expenditures to $3.95 – $4.00 billion (from ~$3.9 billion)
  • Q4 2026 oil production guidance of 518 – 528 MBO/d (1,025 – 1,045 MBOE/d)
  • Q4 2026 cash capital expenditures guidance of $1,000 – $1,050 million

RECENT HIGHLIGHTS

  • Have repurchased 389,841 shares of common stock in Q4 2026 to date for approximately $73 million
  • On October 1, redeemed all $698 million in aggregate principal amount of the Company’s 2026 Senior Notes at par
  • Repurchased $195 million in aggregate principal amount of 2054 and 2064 Senior Notes at a weighted average price of 91.0% of par ($183 million, including accrued interest)

THIRD QUARTER 2026 OPERATIONS UPDATE

The following tables provide a summary of Diamondback’s key operational updates:

Wells Drilled and Completed:

    Three Months Ended September 30, 2026   Nine Months Ended September 30, 2026
    Drilled   Completed   Drilled   Completed
    Gross   Net   Gross   Net   Gross   Net   Gross   Net
Total   105   100   135   133   320   300   450   427


Gross Wells Drilled and Completed By Zone:

    Three Months Ended September 30, 2026   Nine Months Ended September 30, 2026
    Number of Wells Drilled   Number of Wells Completed   Number of Wells Drilled   Number of Wells Completed
Midland Basin:                
Upper Spraberry   3   2   6   5
Middle Spraberry   5   6   18   26
Jo Mill   17   22   55   84
Lower Spraberry   15   24   55   87
Dean   3   2   5   13
Wolfcamp A   15   36   61   105
Wolfcamp B   24   33   69   104
Wolfcamp D   9   8   27   23
Barnett   14   2   24   3
Midland Basin Total   105   135   320   450
                 
Average Completed Lateral Length (in feet)       13,584       12,251


Realized Average Prices:

    Three Months Ended
    September 30, 2026   June 30, 2026   September 30, 2025
Oil ($ per Bbl)   $ 87.30   $ 96.82     $ 64.60
Natural gas ($ per Mcf)   $ 1.12   $ (2.15 )   $ 0.75
Natural gas liquids ($ per Bbl)   $ 20.02   $ 18.56     $ 17.28
Combined price ($ per BOE)   $ 51.03   $ 51.68     $ 39.73
             
Oil, hedged ($ per Bbl)(1)   $ 85.89   $ 94.33     $ 63.70
Natural gas, hedged ($ per Mcf)(1)   $ 0.90   $ (0.34 )   $ 1.75
Natural gas liquids, hedged ($ per Bbl)(1)   $ 20.02   $ 18.56     $ 17.28
Combined price, hedged ($ per BOE)(1)   $ 50.01   $ 52.90     $ 40.58
(1) Hedged prices reflect the effect of our commodity derivative transactions on our average sales prices and include gains and losses on cash settlements for matured commodity derivatives, which we do not designate for hedge accounting. Hedged prices exclude gains or losses resulting from the early settlement of commodity derivative contracts.


Average Cash Costs per BOE:

    Three Months Ended
    September 30, 2026   June 30, 2026   September 30, 2025
Lease operating expenses   $ 5.97   $ 5.96   $ 5.65
Production and ad valorem taxes     3.02     3.26     2.44
Gathering, processing and transportation expense     1.32     1.22     1.41
General and administrative – cash component     0.60     0.52     0.55
Total operating expense – cash   $ 10.91   $ 10.96   $ 10.05


FINANCIAL UPDATE

Earnings Attributable to Diamondback Energy, Inc.:

    Three Months Ended September 30, 2026
    (in millions, except per share amounts)
Net income (loss) attributable to Diamondback Energy, Inc.   $ 1,603
Earnings (loss) per common share attributable to Diamondback Energy, Inc. – Diluted(1)   $ 5.69
Adjusted net income(1)   $ 1,649
Adjusted net income per common share – Diluted(1)   $ 5.86
(1) The Company’s earnings (loss) per diluted share amount has been computed using the two-class method in accordance with GAAP. The two-class method is an earnings allocation which reflects the respective ownership among holders of common stock and participating securities. Diluted earnings per share using the two-class method is calculated as (i) net income attributable to Diamondback Energy, Inc., (ii) less the reallocation of $9 million in earnings attributable to participating securities, (iii) divided by diluted weighted average common shares outstanding for the respective periods.


Cash Capital Expenditures:

    Three Months Ended September 30,   Nine Months Ended September 30,
    2026   2025   2026   2025
    (in millions)
Operated drilling and completion additions to oil and natural gas properties   $ 884   $ 632   $ 2,510   $ 2,203
Non-operated additions to oil and natural gas properties and other     142     142     445     377
Total   $ 1,026   $ 774   $ 2,955   $ 2,580


Adjusted EBITDA and Free Cash Flow – Non-GAAP:

    Three Months Ended September 30, 2026   Nine Months Ended September 30, 2026
    (in millions)
Net income (loss) attributable to Diamondback Energy, Inc.   $ 1,603   $ 3,510
Consolidated Adjusted EBITDA   $ 3,752   $ 10,693
Adjusted EBITDA attributable to Diamondback Energy, Inc.   $ 3,393   $ 9,646
Net cash provided by operating activities   $ 2,599   $ 8,016
Free Cash Flow   $ 2,148   $ 6,183
Adjusted Free Cash Flow   $ 2,150   $ 6,218


Debt & Liquidity:

  September 30, 2026
  (in millions)
Standalone cash $ 548
Borrowings outstanding under the credit facility $ —
Remaining availability under the credit facility $ 3,000
Total standalone liquidity $ 3,548
Consolidated total debt $ 13,375
Consolidated total net debt $ 12,817


RETURN OF CAPITAL UPDATE

Diamondback announced today that the Company’s Board of Directors (the “Board”) approved a 7.3% increase to the Company’s base cash dividend, raising it to $1.18 per common share for the third quarter of 2026, payable on November 19, 2026, to stockholders of record at the close of business on November 12, 2026.

During the third quarter, the Company repurchased 1,348,209 shares of common stock for approximately $251 million at a weighted average price of $185.94 per share (excluding excise tax). The Company expects to continue repurchases opportunistically using cash on hand, free cash flow and potential asset sale proceeds. The program has no time limit and may be suspended, modified or discontinued at the Board’s discretion. Repurchases may be executed in privately negotiated or open-market transactions, consistent with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, and will be subject to market conditions, applicable regulatory and legal requirements and other factors. All shares repurchased will be retired.

The table below summarizes Diamondback’s return of capital program, including dividends and share repurchases, with future actions subject to Board approval.

    Q32026   Q42026to date   Cumulative
    (in millions, except per share amounts, shares in thousands)
Base dividend   $ 1.18        
Shares repurchased     1,348     390     44,183
Weighted average repurchase price   $ 185.94   $ 186.69   $ 143.66
Total repurchase cost   $ 251   $ 73   $ 6,348
             
Total return of capital   $ 582        


UPDATED 2026 GUIDANCE

Below is Diamondback’s and Viper Energy, Inc.’s (“Viper”) updated guidance for the full year 2026, which includes fourth quarter production and capital guidance.

  2026 Guidance 2026 Guidance
  Diamondback Energy, Inc. Viper Energy, Inc.
     
2026 Net production – MBOE/d ~1,015 (from 1,000+) 137.0 – 138.0
2026 Oil production – MBO/d ~524 (from 522+) 67.25 – 67.75
Q4 2026 Oil production – MBO/d (total – MBOE/d) 518 – 528 (1,025 – 1,045) 70.0 – 71.0 (141.5 – 143.5)
     
Unit costs ($/BOE)    
Lease operating expenses, including workovers $5.95 – $6.20 (from $5.90 – $6.40)  
G&A    
Cash G&A $0.55 – $0.65 $0.70 – $0.90
Non-cash equity-based compensation $0.20 – $0.30 $0.10 – $0.20
DD&A $13.50 – $14.50 $14.75 – $17.25
Interest expense (net of interest income) $0.50 – $0.70 $1.90 – $2.40
Gathering, processing and transportation $1.30 – $1.50 (from $1.40 – $1.60)  
     
Production and ad valorem taxes (% of revenue) ~6.5% (from ~7%) ~7%
Corporate tax rate (% of pre-tax income) 23%  
Cash tax rate (% of pre-tax income)(1) 19% – 22% 27% – 30%
Q4 2026 Cash taxes ($ – million) $500 – $560  
     
Cash Capital Budget ($ – million)    
Operated drilling and completion $3,350 – $3,400 (from ~$3,310)  
2026 Total capital expenditures(2) $3,950 – $4,000 (from ~$3,900)  
Q4 2026 Capital expenditures $1,000 – $1,050  
     
Average lateral length (Ft.) ~12,900′  
Net lateral footage completed (1,000’s of Ft.) 6,200′ – 6,600′ (from 6,100′ – 6,500′)  
(1) Pre-tax income attributable to the Company is a non-GAAP measure. We are not able to forecast the most directly comparable GAAP measure – Income (loss) before income taxes – due to high variability and difficulty in predicting certain items that affect Income (loss) before income taxes, such as future commodity prices, pace of and costs of developing, producing and operating our interests in oil and natural gas properties, future changes in interest rates and various other business factors impacting our financial results.
(2) Includes non-operated drilling and completion, capital workovers, science, infrastructure, midstream and environmental.

CONFERENCE CALL

Diamondback will host a conference call and webcast for investors and analysts to discuss its results for the third quarter of 2026 on Tuesday, November 3, 2026 at 8:00 a.m. CT. Access to the webcast, and replay which will be available following the call, may be found here. The live webcast of the earnings conference call will also be available via Diamondback’s website at www.diamondbackenergy.com under the “Investor Relations” section of the site. Investors and others should note that Diamondback announces material financial and operational information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The information we post through our investor relations website may be deemed material. Accordingly, investors should monitor our investor relations website in addition to following our press releases, SEC filings and public conference calls and webcasts.

About Diamondback Energy, Inc.

Diamondback is an independent oil and natural gas company headquartered in Midland, Texas focused on the acquisition, development, exploration and exploitation of unconventional, onshore oil and natural gas reserves primarily in the Permian Basin in West Texas. For more information, please visit www.diamondbackenergy.com.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, including statements regarding Diamondback’s: future performance; business strategy; future operations (including drilling plans and capital plans); estimates and projections of revenues, losses, costs, expenses, returns, cash flow, and financial position; reserve estimates and its ability to replace or increase reserves; anticipated benefits or other effects of strategic transactions (including the 2026 Drop Down, the Viper Riverbend acquisition, the Viper McElroy Ranch acquisition and Viper’s Sitio acquisition and other acquisitions, divestitures or reorganizations); and plans and objectives of management (including plans for future cash flow from operations and for executing environmental strategies) are forward-looking statements. When used in this news release, the words “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “guidance,” “intend,” “may,” “model,” “outlook,” “plan,” “positioned,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions (including the negative of such terms) are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Although Diamondback believes that the expectations and assumptions reflected in its forward-looking statements are reasonable as and when made, they involve risks and uncertainties that are difficult to predict and, in many cases, beyond Diamondback’s control. Accordingly, forward-looking statements are not guarantees of future performance and Diamondback’s actual outcomes could differ materially from what Diamondback has expressed in its forward-looking statements.

Factors that could cause the outcomes to differ materially include (but are not limited to) the following: geopolitics and market conditions, including changes in supply and demand levels for oil, natural gas, and natural gas liquids, and the resulting impact on the price for those commodities; changes in U.S. energy, environmental, monetary and trade policies, including with respect to tariffs or other trade barriers and any resulting trade tensions; actions taken by the members of OPEC and its non-OPEC allies (OPEC+) affecting the production and pricing of oil, as well as other domestic and global political, economic, or diplomatic developments; changes in general economic, business or industry conditions, including changes in foreign currency exchange rates, interest rates, inflation rates, and instability in the financial markets; regional supply and demand factors, including delays, curtailments or interruptions of production, or governmental orders, rules or regulations that impose production limits; federal and state legislative and regulatory initiatives relating to hydraulic fracturing, including the effect of existing and future laws and governmental regulations; physical and transition risks relating to climate change, changing political and social perspectives on climate change and other environmental, social and governance factors, and risks from our publicly disclosed targets related to sustainability and emissions reduction initiatives; challenges in developing our existing leasehold acreage and finding, developing or acquiring additional reserves; restrictions on the use of water, including limits on the use of produced water and a moratorium on new produced water disposal well permits recently imposed by the Texas Railroad Commission in an effort to control induced seismicity in the Permian Basin; significant declines in prices for oil, natural gas, or natural gas liquids, which could require recognition of significant impairment charges; conditions in the capital, financial and credit markets, including the availability and pricing of capital for acquisitions, exploration and development operations; challenges with employee retention and an increasingly competitive labor market; changes in availability or cost of rigs, equipment, raw materials, supplies and oilfield services; changes in safety, health, environmental, tax and other regulations or requirements (including those addressing air emissions, water management, or the impact of global climate change); security threats, including cybersecurity threats and disruptions to our business and operations from breaches of our information technology systems, or from breaches of information technology systems of third parties with whom we transact business; lack of, or disruption in, access to adequate and reliable electrical power, internet and telecommunication infrastructure, information and computer systems, transportation, processing, storage and other facilities for our oil, natural gas and natural gas liquids; failures or delays in achieving expected reserve or production levels from existing and future oil and natural gas developments, including due to operating hazards, drilling risks, or the inherent uncertainties in predicting reserve and reservoir performance; inability to keep pace with technological developments in our industry; failure to meet our obligations under our oil purchase contracts; loss of one or more customers or their inability to meet their obligations; geographical concentration of our primary operations; risks from our return of capital activity, and uncertainties over our future dividends and share repurchases; difficulty in obtaining necessary approvals and permits; severe weather conditions and natural disasters; changes in the financial strength of counterparties to our credit facilities and hedging contracts; our substantial indebtedness and restrictions to our operating and financial flexibility; changes in our credit rating; failure to identify, complete and successfully integrate acquisitions, including Viper’s Riverbend acquisition, Viper’s McElroy Ranch acquisition and Viper’s Sitio acquisition; the Endeavor stockholders’ ability to significantly influence our business and potential conflicts of interest; and other risks described in Part I, Item 1A of Diamondback’s Annual Report on Form 10-K, filed with the SEC on February 25, 2026, and those risks disclosed in its subsequent filings on Forms 10-K, 10-Q and 8-K, which can be obtained free of charge on the SEC’s website at http://www.sec.gov and Diamondback’s website at www.diamondbackenergy.com/investors.

In light of these factors, the events anticipated by Diamondback’s forward-looking statements may not occur at the time anticipated or at all. Moreover, Diamondback operates in a very competitive and rapidly changing environment and new risks emerge from time to time. Diamondback cannot predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those anticipated by any forward-looking statements it may make. Accordingly, you should not place undue reliance on any forward-looking statements. All forward-looking statements speak only as of the date of this release or, if earlier, as of the date they were made. Diamondback does not intend to, and disclaims any obligation to, update or revise any forward-looking statements unless required by applicable law.

Diamondback Energy, Inc.
Condensed Consolidated Statements of Operations
(unaudited, in millions, except per share amounts, shares in thousands)
                 
    Three Months Ended September 30,   Nine Months Ended September 30,
      2026       2025       2026       2025  
Revenues:                
Oil, natural gas and natural gas liquid sales   $ 4,854     $ 3,447     $ 13,465     $ 10,420  
Sales of purchased oil     536       459       1,660       1,168  
Other operating income     41       18       108       62  
Total revenues     5,431       3,924       15,233       11,650  
Costs and expenses:                
Lease operating expenses     568       490       1,667       1,338  
Production and ad valorem taxes     287       212       857       654  
Gathering, processing and transportation     126       122       359       378  
Purchased oil expense     540       455       1,663       1,168  
Depreciation, depletion, amortization and accretion     1,320       1,286       3,885       3,649  
Impairment of oil and natural gas properties     —       —       1,400       —  
General and administrative expenses     83       70       234       210  
Other operating expenses, net     7       53       40       205  
Total costs and expenses     2,931       2,688       10,105       7,602  
Income (loss) from operations     2,500       1,236       5,128       4,048  
Other income (expense):                
Interest expense, net     (55 )     (70 )     (174 )     (166 )
Other income (expense), net     5       116       8       153  
Gain (loss) on derivative instruments, net     (182 )     120       (16 )     149  
Gain (loss) on extinguishment of debt, net     4       (32 )     137       23  
Total other income (expense), net     (228 )     134       (45 )     159  
Income (loss) before income taxes     2,272       1,370       5,083       4,207  
Provision for (benefit from) income taxes     501       287       1,113       894  
Net income (loss)     1,771       1,083       3,970       3,313  
Net income (loss) attributable to non-controlling interest     168       65       460       191  
Net income (loss) attributable to Diamondback Energy, Inc.   $ 1,603     $ 1,018     $ 3,510     $ 3,122  
                 
Earnings (loss) per common share:                
Basic   $ 5.69     $ 3.51     $ 12.41     $ 10.71  
Diluted   $ 5.69     $ 3.51     $ 12.41     $ 10.71  
Weighted average common shares outstanding:                
Basic     279,959       288,826       281,307       290,188  
Diluted     279,959       288,826       281,307       290,188  

Diamondback Energy, Inc.
Condensed Consolidated Balance Sheets
(unaudited, in millions, except share amounts)
         
    September 30,   December 31,
      2026       2025  
Assets        
Current assets:        
Cash and cash equivalents ($10 million and $13 million related to Viper)   $ 558     $ 104  
Restricted cash     2       2  
Accounts receivable:        
Joint interest and other, net     247       258  
Oil and natural gas sales, net ($496 million and $262 million related to Viper)     2,118       1,128  
Inventories     64       86  
Prepaid expenses and other current assets     158       337  
Total current assets     3,147       1,915  
Property and equipment:        
Oil and natural gas properties:        
Proved properties ($10,102 million and $9,746 million related to Viper)     77,090       71,588  
Unproved properties ($5,213 million and $4,910 million related to Viper)     22,990       23,941  
Other property, equipment and land     932       874  
Accumulated depletion, depreciation, amortization and impairment ($3,062 million and $2,455 million related to Viper)     (33,000 )     (27,782 )
Property and equipment, net     68,012       68,621  
Other assets     951       523  
Total assets   $ 72,110     $ 71,059  
Liabilities and Stockholders’ Equity        
Current liabilities:        
Accounts payable and accrued capital expenditures     1,374       1,168  
Current maturities of debt     1,548       763  
Other accrued liabilities     1,033       1,108  
Revenues and royalties payable     1,645       1,397  
Derivative instruments     47       15  
Income taxes payable     92       149  
Total current liabilities     5,739       4,600  
Long-term debt ($2,394 million and $2,186 million related to Viper)     11,682       13,726  
Deferred income taxes     8,936       9,141  
Other long-term liabilities     620       625  
Total liabilities     26,977       28,092  
Stockholders’ equity:        
Common stock, $0.01 par value; 800,000,000 shares authorized; 279,241,756 and 284,594,908 shares issued and outstanding at September 30, 2026, and December 31, 2025, respectively     3       3  
Additional paid-in capital     31,638       32,236  
Retained earnings (accumulated deficit)     7,332       4,740  
Accumulated other comprehensive income (loss)     (7 )     (7 )
Total Diamondback Energy, Inc. stockholders’ equity     38,966       36,972  
Non-controlling interest     6,167       5,995  
Total equity     45,133       42,967  
Total liabilities and stockholders’ equity   $ 72,110     $ 71,059  

Diamondback Energy, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited, in millions)
                 
    Three Months Ended September 30,   Nine Months Ended September 30,
      2026       2025       2026       2025  
Cash flows from operating activities:                
Net income (loss)   $ 1,771     $ 1,083     $ 3,970     $ 3,313  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:                
Provision for (benefit from) deferred income taxes     (7 )     253       (213 )     235  
Depreciation, depletion, amortization and accretion     1,320       1,286       3,885       3,649  
Impairment of oil and natural gas properties     —       —       1,400       —  
(Gain) loss on extinguishment of debt, net     (4 )     32       (137 )     (23 )
(Gain) loss on derivative instruments, net     182       (120 )     16       (149 )
Cash received (paid) on settlement of derivative instruments     (97 )     60       149       108  
Other     9       (60 )     68       (6 )
Changes in operating assets and liabilities:                
Accounts receivable     (476 )     (22 )     (1,039 )     138  
Accounts payable and accrued liabilities     71       28       (133 )     (355 )
Income taxes payable     (138 )     (206 )     (138 )     (515 )
Revenues and royalties payable     (54 )     58       270       28  
Other     22       (9 )     (82 )     (8 )
Net cash provided by (used in) operating activities     2,599       2,383       8,016       6,415  
Cash flows from investing activities:                
Additions to oil and natural gas properties     (1,026 )     (774 )     (2,955 )     (2,580 )
Property acquisitions     (1,157 )     (1,536 )     (1,909 )     (5,411 )
Proceeds from sale of assets     66       257       723       314  
Other     (193 )     (6 )     (222 )     (14 )
Net cash provided by (used in) investing activities     (2,310 )     (2,059 )     (4,363 )     (7,691 )
Cash flows from financing activities:                
Proceeds from debt     3,115       4,400       9,405       13,022  
Repayment of debt     (2,500 )     (3,313 )     (10,547 )     (9,720 )
Repurchased shares under repurchase program     (251 )     (603 )     (431 )     (1,576 )
Repurchased shares – related party     —       —       (509 )     —  
Repurchased shares/units under Viper’s repurchase program     (90 )     (90 )     (318 )     (100 )
Net proceeds from Viper’s issuance of common stock     —       —       —       1,232  
Proceeds from sale of Viper’s common stock     —       —       589       —  
Payments for dividends and dividend equivalents     (309 )     (290 )     (918 )     (874 )
Dividends to non-controlling interest     (158 )     (79 )     (437 )     (256 )
Other     —       (18 )     (33 )     (64 )
Net cash provided by (used in) financing activities     (193 )     7       (3,199 )     1,664  
Net increase (decrease) in cash, cash equivalents and restricted cash     96       331       454       388  
Cash, cash equivalents and restricted cash at beginning of period     464       221       106       164  
Cash, cash equivalents and restricted cash at end of period   $ 560     $ 552     $ 560     $ 552  

Diamondback Energy, Inc.
Selected Operating Data
(unaudited)
                 
    Three Months Ended
    September 30, 2026
  June 30, 2026   September 30, 2025
Production Data:                
Oil (MBbls)     48,295       47,791       46,345  
Natural gas (MMcf)     135,002       128,279       115,353  
Natural gas liquids (MBbls)     24,330       23,436       21,180  
Combined volumes (MBOE)(1)     95,125       92,607       86,751  
                 
Daily oil volumes (BO/d)     524,946       525,176       503,750  
Daily combined volumes (BOE/d)     1,033,967       1,017,659       942,946  
                 
Average Prices:                
Oil ($ per Bbl)   $ 87.30     $ 96.82     $ 64.60  
Natural gas ($ per Mcf)   $ 1.12     $ (2.15 )   $ 0.75  
Natural gas liquids ($ per Bbl)   $ 20.02     $ 18.56     $ 17.28  
Combined price ($ per BOE)   $ 51.03     $ 51.68     $ 39.73  
                 
Oil, hedged ($ per Bbl)(2)   $ 85.89     $ 94.33     $ 63.70  
Natural gas, hedged ($ per Mcf)(2)   $ 0.90     $ (0.34 )   $ 1.75  
Natural gas liquids, hedged ($ per Bbl)(2)   $ 20.02     $ 18.56     $ 17.28  
Combined price, hedged ($ per BOE)(2)   $ 50.01     $ 52.90     $ 40.58  
                 
Average Cash Costs ($/BOE):                
Lease operating expenses   $ 5.97     $ 5.96     $ 5.65  
Production and ad valorem taxes     3.02       3.26       2.44  
Gathering, processing and transportation expense     1.32       1.22       1.41  
General and administrative – cash component     0.60       0.52       0.55  
Total operating expense – cash   $ 10.91     $ 10.96     $ 10.05  
                 
General and administrative – non-cash component   $ 0.27     $ 0.26     $ 0.25  
Depreciation, depletion, amortization and accretion   $ 13.88     $ 13.74     $ 14.82  
Interest expense, net   $ 0.58     $ 0.60     $ 0.81  
(1) Bbl equivalents are calculated using a conversion rate of six Mcf per one Bbl.
(2) Hedged prices reflect the effect of our commodity derivative transactions on our average sales prices and include gains and losses on cash settlements for matured commodity derivatives, which we do not designate for hedge accounting. Hedged prices exclude gains or losses resulting from the early settlement of commodity derivative contracts.


NON-GAAP FINANCIAL MEASURES

ADJUSTED EBITDA

Adjusted EBITDA is a supplemental non-GAAP financial measure that is used by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. The Company defines Adjusted EBITDA as net income (loss) attributable to Diamondback Energy, Inc., plus net income (loss) attributable to non-controlling interest (“net income (loss)”) before non-cash (gain) loss on derivative instruments, net, interest expense, net, depreciation, depletion, amortization and accretion, depreciation and interest expense related to equity method investments, (gain) loss on extinguishment of debt, impairment of oil and natural gas properties, non-cash equity-based compensation expense, capitalized equity-based compensation expense, other non-cash transactions and provision for (benefit from) income taxes. Adjusted EBITDA is not a measure of net income as determined by United States generally accepted accounting principles (“GAAP”). Management believes Adjusted EBITDA is useful because the measure allows it to evaluate the Company’s operating performance and compare the results of its operations from period to period without regard to its financing methods or capital structure. The Company excludes the items listed above from net income (loss) to determine Adjusted EBITDA because these amounts can vary substantially from company to company within its industry depending upon accounting methods and book values of assets, capital structures and the method by which the assets were acquired. Further, the Company excludes the effects of significant transactions that may affect earnings but are unpredictable in nature, timing and amount, although they may recur in different reporting periods. Adjusted EBITDA should not be considered as an alternative to, or more meaningful than, net income as determined in accordance with GAAP or as an indicator of the Company’s operating performance. Certain items excluded from Adjusted EBITDA are significant components in understanding and assessing a company’s financial performance, such as a company’s cost of capital and tax structure, as well as the historic costs of depreciable assets. The Company’s computation of Adjusted EBITDA may not be comparable to other similarly titled measures of other companies or to such measure in our credit facility or any of our other contracts.

The following tables present a reconciliation of the GAAP financial measure of net income (loss) attributable to Diamondback Energy, Inc. to the non-GAAP financial measure of Adjusted EBITDA:

Diamondback Energy, Inc.
Reconciliation of Net Income (Loss) to Adjusted EBITDA
(unaudited, in millions)
         
    Three Months Ended September 30, 2026   Nine Months Ended September 30, 2026
Net income (loss) attributable to Diamondback Energy, Inc.   $ 1,603     $ 3,510  
Net income (loss) attributable to non-controlling interest     168       460  
Net income (loss)     1,771       3,970  
Non-cash (gain) loss on derivative instruments, net     85       165  
Interest expense, net     55       174  
Depreciation, depletion, amortization and accretion     1,320       3,885  
Depreciation and interest expense related to equity method investments     13       39  
(Gain) loss on extinguishment of debt     (4 )     (137 )
Impairment of oil and natural gas properties     —       1,400  
Non-cash equity-based compensation expense     37       101  
Capitalized equity-based compensation expense     (11 )     (29 )
Other non-cash transactions     (15 )     12  
Provision for (benefit from) income taxes     501       1,113  
Consolidated Adjusted EBITDA     3,752       10,693  
Less: Adjustment for non-controlling interest     359       1,047  
Adjusted EBITDA attributable to Diamondback Energy, Inc.   $ 3,393     $ 9,646  


ADJUSTED NET INCOME

Adjusted net income is a non-GAAP financial measure equal to net income (loss) attributable to Diamondback Energy, Inc. plus net income (loss) attributable to non-controlling interest (“net income (loss)”) adjusted for non-cash (gain) loss on derivative instruments, net, (gain) loss on extinguishment of debt, other non-cash transactions and related income tax adjustments. The Company’s computation of adjusted net income may not be comparable to other similarly titled measures of other companies or to such measure in our credit facility or any of our other contracts. Management believes adjusted net income helps investors in the oil and natural gas industry to measure and compare the Company’s performance to other oil and natural gas companies by excluding from the calculation items that can vary significantly from company to company depending upon accounting methods, the book value of assets and other non-operational factors. Further, in order to allow investors to compare the Company’s performance across periods, the Company excludes the effects of significant transactions that may affect earnings but are unpredictable in nature, timing and amount, although they may recur in different reporting periods.

The following table presents a reconciliation of the GAAP financial measure of net income (loss) attributable to Diamondback Energy, Inc. to the non-GAAP measure of adjusted net income:

Diamondback Energy, Inc.
Adjusted Net Income
(unaudited, in millions, except per share amounts, shares in thousands)
     
    Three Months Ended
    September 30, 2026
    Amounts   Amounts Per Diluted Share
Net income (loss) attributable to Diamondback Energy, Inc.(1)   $ 1,603     $ 5.69  
Net income (loss) attributable to non-controlling interest     168       0.60  
Net income (loss)(1)     1,771       6.29  
Non-cash (gain) loss on derivative instruments, net     85       0.30  
(Gain) loss on extinguishment of debt     (4 )     (0.01 )
Other non-cash transactions     (15 )     (0.05 )
Adjusted net income excluding above items(1)     1,837       6.53  
Income tax adjustment for above items     (15 )     (0.05 )
Adjusted net income(1)     1,822       6.48  
Less: Adjusted net income attributable to non-controlling interest     173       0.62  
Adjusted net income attributable to Diamondback Energy, Inc.(1)   $ 1,649     $ 5.86  
         
Weighted average common shares outstanding:        
Basic             279,959  
Diluted             279,959  
(1) The Company’s earnings (loss) per diluted share amount has been computed using the two-class method in accordance with GAAP. The two-class method is an earnings allocation which reflects the respective ownership among holders of common stock and participating securities. Diluted earnings per share using the two-class method is calculated as (i) net income attributable to Diamondback Energy, Inc., (ii) less the reallocation of $9 million in earnings attributable to participating securities, (iii) divided by diluted weighted average common shares outstanding for the respective periods.


OPERATING CASH FLOW BEFORE WORKING CAPITAL CHANGES, FREE CASH FLOW AND ADJUSTED FREE CASH FLOW

Operating cash flow before working capital changes, which is a non-GAAP financial measure, represents net cash provided by operating activities as determined under GAAP without regard to changes in working capital. The Company believes operating cash flow before working capital changes is a useful measure of an oil and natural gas company’s ability to generate cash used to fund exploration, development and acquisition activities and service debt or pay dividends. The Company also uses this measure because changes in working capital relate to the timing of cash receipts and disbursements that the Company may not control and may not relate to the period in which the operating activities occurred. This allows the Company to compare its operating performance with that of other companies without regard to financing methods and capital structure.

The Company defines Free Cash Flow, which is a non-GAAP financial measure, as cash flow from operating activities before changes in working capital in excess of cash capital expenditures. The Company defines Adjusted Free Cash Flow, which is a non-GAAP financial measure, as Free Cash Flow before the tax impact from divestitures (if any), merger and transaction expenses, costs of early termination of derivatives and settlements of any treasury locks (if any). The Company believes that Free Cash Flow and Adjusted Free Cash Flow are useful to investors as they provide a measure to compare both cash flow from operating activities and additions to oil and natural gas properties across periods on a consistent basis, adjusted, as applicable, for non-recurring impacts from divestitures, merger and transaction expenses, the early termination of derivative contracts and settlements of treasury locks. These measures should not be considered as an alternative to, or more meaningful than, net cash provided by operating activities as an indicator of liquidity. The Company’s computation of Free Cash Flow may not be comparable to other similarly titled measures of other companies.

The following tables present a reconciliation of the GAAP financial measure of net cash provided by operating activities to the non-GAAP measure of operating cash flow before working capital changes and to the non-GAAP measures of Free Cash Flow and Adjusted Free Cash Flow:

Diamondback Energy, Inc.
Operating Cash Flow Before Working Capital Changes, Free Cash Flow and Adjusted Free Cash Flow
(unaudited, in millions)
         
    Three Months Ended September 30, 2026   Nine Months Ended September 30, 2026
Net cash provided by operating activities   $ 2,599     $ 8,016  
Less: Changes in cash due to changes in operating assets and liabilities:        
Accounts receivable     (476 )     (1,039 )
Accounts payable and accrued liabilities     71       (133 )
Income taxes payable     (138 )     (138 )
Revenues and royalties payable     (54 )     270  
Other     22       (82 )
Total working capital changes     (575 )     (1,122 )
Operating cash flow before working capital changes     3,174       9,138  
Additions to oil and natural gas properties     (1,026 )     (2,955 )
Total Cash CAPEX     (1,026 )     (2,955 )
Free Cash Flow     2,148       6,183  
Merger and transaction expenses(1)     2       8  
Early termination of derivatives     —       27  
Adjusted Free Cash Flow   $ 2,150     $ 6,218  
(1) Includes $4 million of Viper’s transaction expenses primarily related to the Sitio Acquisition for the nine months ended September 30, 2026.


NET DEBT

The Company defines the non-GAAP measure of net debt as total debt (excluding debt issuance costs, discounts, premiums and unamortized basis adjustments) less cash and cash equivalents and restricted cash that has been irrevocably deposited for the redemption of principal amounts of outstanding senior notes. Net debt should not be considered an alternative to, or more meaningful than, total debt, the most directly comparable GAAP measure. Management uses net debt to determine the Company’s outstanding debt obligations that would not be readily satisfied by its cash and cash equivalents on hand. The Company believes this metric is useful to analysts and investors in determining the Company’s leverage position because the Company has the ability to, and may decide to, use a portion of its cash and cash equivalents to reduce debt.

Diamondback Energy, Inc.
Net Debt
(unaudited, in millions)
                         
    September 30, 2026   Net Q3 Principal Borrowings/ (Repayments)   June 30, 2026   March 31, 2026   December 31, 2025   September 30, 2025
Diamondback total debt(1)   $ 10,965     $ (106 )   $ 11,071     $ 12,448     $ 12,462     $ 13,792  
Diamondback cash and cash equivalents     (548 )         (385 )     (146 )     (91 )     (106 )
Diamondback net debt   $ 10,417         $ 10,686     $ 12,302     $ 12,371     $ 13,686  
                         
Viper total debt(1)   $ 2,410     $ 715     $ 1,695     $ 1,620     $ 2,205     $ 2,640  
Viper cash and cash equivalents     (10 )         (77 )     (28 )     (13 )     (433 )
Viper net debt   $ 2,400         $ 1,618     $ 1,592     $ 2,192     $ 2,207  
                         
Total debt   $ 13,375     $ 609     $ 12,766     $ 14,068     $ 14,667     $ 16,432  
Cash and cash equivalents     (558 )         (462 )     (174 )     (104 )     (539 )
Net debt   $ 12,817         $ 12,304     $ 13,894     $ 14,563     $ 15,893  
(1) Excludes debt issuance costs, discounts, premiums and unamortized basis adjustments.


DERIVATIVES

As of October 30, 2026, the Company had the following outstanding consolidated derivative contracts, including derivative contracts at Viper. The Company’s derivative contracts are based upon reported settlement prices on commodity exchanges and published index prices. Crude oil derivative settlements are based on New York Mercantile Exchange (“NYMEX”) West Texas Intermediate (“WTI”) pricing, Crude Oil Brent pricing and the regional crude oil pricing points indicated below. Natural gas derivative settlements are based on NYMEX Henry Hub pricing and the regional natural gas pricing points indicated below. Basis swaps settle on the differential between the applicable benchmark price and the regional index price, and roll swaps settle on the differential between NYMEX WTI prompt-month and second-month contract prices. When aggregating multiple contracts, the weighted average contract price is disclosed.

    Crude Oil (Bbls/day, $/Bbl)
    Q4 2026   Q1 2027   Q2 2027   Q3 2027   Q4 2027
Long Puts – Crude Brent Oil     10,000     15,000     10,000     —     —
Long Put Price ($/Bbl)   $ 55.00   $ 55.00   $ 55.00     —     —
Deferred Premium ($/Bbl)   $ -1.33   $ -1.27   $ -1.21     —     —
Long Puts – WTI (Magellan East Houston)     75,000     75,000     60,000     30,000     10,000
Long Put Price ($/Bbl)   $ 50.67   $ 50.00   $ 50.00   $ 50.00   $ 50.00
Deferred Premium ($/Bbl)   $ -1.31   $ -1.25   $ -1.25   $ -1.15   $ -0.98
Long Puts – WTI (Cushing)     175,000     140,000     130,000     90,000     40,000
Long Put Price ($/Bbl)   $ 50.57   $ 50.00   $ 50.00   $ 50.00   $ 50.00
Deferred Premium ($/Bbl)   $ -1.28   $ -1.28   $ -1.24   $ -1.22   $ -1.15
Basis Swaps – WTI (Midland)     85,000     41,500     41,500     31,500     31,500
$ 1.09   $ 1.30   $ 1.30   $ 1.07   $ 1.07
WTI / Brent Basis Puts     290,000     —     —     —     —
Spread ($/Bbl)   $ -41.03     —     —     —     —
Deferred Premium ($/Bbl)   $ -1.44     —     —     —     —
Roll Swaps – WTI     150,000     —     —     —     —
$ 2.89     —     —     —     —

    Natural Gas (Mmbtu/day, $/Mmbtu)
    Q4 2026   FY 2027   FY 2028
Costless Collars – Henry Hub     840,000     720,000     130,000
Floor Price ($/Mmbtu)   $ 2.87   $ 2.88   $ 2.65
Ceiling Price ($/Mmbtu)   $ 6.35   $ 6.37   $ 5.88
Natural Gas Basis Swaps – Waha Hub     650,000     370,000     60,000
$ -1.75   $ -1.27   $ -1.51
Natural Gas Basis Swaps – Houston Ship Channel     100,000     300,000     150,000
$ -0.35   $ -0.31   $ -0.33

Investor Contact:
Adam Lawlis
+1 432.221.7467
alawlis@diamondbackenergy.com

MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the following investor conferences:

  • Canaccord Genuity Medtech, Diagnostics & Digital Health Services Forum in New York on Wednesday, Nov. 11, 2026. The fireside chat is scheduled at 8:00 a.m. (ET) the same day via webcast.
  • Jefferies Global Healthcare Conference in London on Thursday, Nov. 19, 2026. The Company’s presentation will begin at 1:00 p.m. (GMT) / 9:00 a.m. (ET) the same day via webcast.

A live webcast of the events can be found at ir.cvrx.com. An archived version of the presentation will be available following the live events and can be accessed at the same location for a limited time.

About CVRx, Inc.

CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.